Modified HIV-pol polypeptide having immunological activity for use as diagnostic reagent

ABSTRACT

A polypeptide having immunological activity for use as a diagnostic reagent for the HIV. The polypeptide comprises a substantial portion of each of more than one of the constituent proteins coded for by the HIV-pol gene, namely the amino acid sequences of the reverse transcriptase, RNase H and integrase enzymes coded for by the HIV-pol gene and the amino acid sequences of part of the protease enzyme coded for by the HIV-pol gene, but omitting the active site responsible for proteolytic activity.

TECHNICAL FIELD

This invention relates to a polypeptide having immunological activity for use as a diagnostic reagent and/or a vaccine component.

BACKGROUND ART

Diagnostic kits for use in screening individuals for infection with human immunodeficiency virus (HIV) infection frequently include reagents comprising HIV antigens which are used to detect antibodies using known immunological techniques including ELISA, Western Blot, latex agglutination and immuno-luminescent and immuno-fluorescent techniques.

The effectiveness of such techniques however depends upon selection of suitable immunological reagents and one particular difficulty which arises is that particular reagents are often specific to individual strains or groups of strains of HIV. Thus, for example, known diagnostic reagents based upon HIV-1 may fail to detect antibodies resulting from an infection of a patient with HIV-2.

Similarly, in the production of vaccines designed to protect individuals against HIV infection, the use of antigens derived from one particular strain of HIV may fail to provide adeguate protection against infection with other strains.

Synthesis and cleavage of the HIV-I pol precursor polyprotein is disclosed in "Processing Protease and Reverse Transcriptase from Human Immunodeficiency Virus Type I Polyprotein in Escherichia coli" by Jan Mous et. al., Journal of Virology, Apr. 1988, p. 1433-1436. The process disclosed in this reference results in the formation of a 92 kDa polypeptide consisting of protease (18 kDa), reverse transcriptase (64 kDa) and an amino-terminal portion of endonuclease (integrase) (10 kDa). The polyprotein is thus lacking the intact endonuclease sequence (25 kDa), and thus lacks substantial antigenic epitopes representing the endonuclease (integrase). Thus, the protein is unlikely to be suited for the preparation of diagnostic tests and vaccines for HIV-I.

It is an object of the present invention to overcome such problems.

DISCLOSURE OF INVENTION

It has now been found that the product of expressing a substantial part of the HIV-pol gene in a suitable host has antigenic properties which allows the above-mentioned problems to be overcome.

Thus according to one aspect of the present invention there is provided the use as an antigenic reagent in the diagnostic test or as a vaccine component of a polypeptide comprising a substantial portion of each of more than one of the constituent proteins coded for by the HIV-pol gene.

Diagnostic kits and vaccines comprising said polypeptide form further aspects of the present invention.

The HIV-pol gene codes for four enzymes, namely a protease, a reverse transcriptase, a ribonuclease referred to as RNAse H and an enzyme referred to as Integrase.

It is believed that during infection of a T cell by HIV a full length precursor is expressed which is then cut up into the discrete proteins listed above. These have the following activities and (it is thought) act in the order indicated:

    ______________________________________     Protease       Precursor cleavage     Reverse Transcriptase                    Preparation of viral DNA from viral                    RNA     RNase H        Destruction of viral RNA leaving                    newly synthesised DNA     Integrase      Insertion of said DNA into host cell                    genome     ______________________________________

According to a preferred aspect of the present invention, said constituent proteins are enzymes coded for by the HIV-pol gene and the polypeptide thus comprises a substantial portion of each of a plurality of enzymes selected from HIV-pol protease, HIV-pol reverse transcriptase, HIV-pol RNAse H and HIV-pol Integrase. Most preferably, the polypeptide comprises substantial portions of all four of said enzymes.

In vivo, the initial product of expressing the HIV-pol gene is cleaved into its individual elements by the protease. The active site for proteolytic activity occurs adjacent the NH₂ -terminus of the expression product, corresponding to the 5'-end of the protease gene.

According to a preferred aspect of the present invention, the polypeptide omits at least that part of the amino acid sequence of the HIV-pol protease gene which codes for the active site responsible for proteolytic activity. By omitting this portion, the integrity of the polypeptide is maintained and it is less liable to degrade.

BRIEF DESCRIPTION OF DRAWINGS

FIGS. 1a and 1b together form a schematic diagram showing the procedure of Example 1;

FIGS. 2a and 2b together show the results of electrophoresis tests carried out in the manner explained in Example 2; and

FIG. 3 is a graph showing the results of the experiments carried out in Example 3.

BEST MODE FOR CARRYING OUT THE INVENTION

The HIV-pol gene of several strains of HIV-1 has been cloned and the corresponding amino acid sequences derived from the determined DNA sequences. The amino acid sequences of ten strains appear in the accompanying Table 1 at the end of this disclosure SEQ ID Nos:1-10, respectively!. In Table 1, the full sequence of strain HIV HXB2 SEQ ID NO:1! is given, whereas for the other nine strains, only sequence differences are listed. As used herein, the term "constituent protein coded for by the HIV-pol gene" refers to a protein having sufficient amino acid homology with the sequence of HIV HXB2 appearing in the accompanying Table so as to result in antibodies raised against the protein cross-reacting with a polypeptide consisting of the precise amino acid sequence of HIV HXB2 SEQ ID NO:1!.

The HIV-pol gene can be expressed to produce the desired polypeptide by various techniques, e.g. some or all of the baculovirus techniques described in U.S. Pat. No. 4,745,051 to Gale E. Smith et al issued on May 17, 1988; Baculovirus Vectors for Expression of Foreign Genes by C. Yong Kang, Advances in Virus Research, Vol. 35, pp 177-192, Academic Press Inc., 1988; A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures, Max D. Summers and Gale E. Smith, May 1987, Texas A&M University; and Baculoviruses as Gene Expression Vectors, Lois K. Miller, Ann. Rev. Microbiol. 42, pp 177-1991; the disclosures of which are incorporated herein by reference. However our Canadian Patent Application Serial No. 591,908 filed on 23rd Feb. 1989 (and equivalent British Patent Application Serial No. 89 04426.7 filed on Feb. 27, 1989 and U.S. patent application Ser. No. 316,768 filed on Feb. 28, 1989) describes and claims an improved baculovirus expression system capable of producing foreign gene proteins at high levels and the use of this expression system is particularly preferred for expressing the polypeptide of the present invention.

The process disclosed in our Canadian patent employs a recombinant baculovirus containing at least a major part of a polyhedrin gene promoter region, a transcription termination sequence of a polyhedrin structural gene, a foreign structural gene (e.g. an HIV-pol gene) having a translation start codon followed by coding sequences and a translation stop codon. The foreign gene is located between the promoter region and the termination sequence. Immediately upstream of the start codon there is a putative insect cell ribosome binding site for the polyhedrin gene effective for overcoming resistance of susceptible insect cells to express the foreign gene at a high level. The putative ribosome binding site comprises at least the final four nucleotides of the sequence 5'-ACCTATAAAT-3' SEQ ID NO:11!.

Example 3 of the Canadian application describes the production of the pol protein of HIV-1 in a baculovirus expression system based on Autographa californica nucleopolyhedrosis virus (ACNPV) and specifies that a recombinant baculovirus designated ACNPV-HIV-YK-pol has been deposited at the American Type Culture Collection of 12301 Parklawn Drive, Rockville Md. 20852, USA under Accession No. ATCC VR 2233. Deposit was made on Nov. 30, 1988. The disclosure of our Canadian Patent Application Serial No. 591,908 is incorporated herein by reference.

Utilising the procedures described in Example 3 of Canadian Patent Application Serial No. 591,908, a polypeptide comprising the protease, RNose H and Integrase enzymes of HIV strain HIV-XB2 may be produced.

The polypeptide can be used as a diagnostic reagent or vaccine component in ways known to persons skilled in the art, e.g. by the techniques indicated in the publication entitled Clinica, Testing for HIV and AIDS, The Next Five Years, George Street Publications Ltd., Richmond, Surrey, UK, the disclosure of which is incorporated herein by reference.

The invention is illustrated in more detail by the following Examples. Example 1 illustrates the production of a modified recombinant plasmid pUC18-Dpol3 having a 273 bp deletion at the 5'-terminus and its expression as polypeptide lacking the first 91 amino acids at the NH₂ -terminus of the HIV-pol protease. Examples 2 and 3 relate to the expression of the polypeptide and its use as a diagnostic reagent.

EXAMPLE 1

Construction of baculovirus transfer vector containing HIV-1 pol gene with 273 bp deletion at 5' terminus

As illustrated in FIGS. 1a and 1b the BglII and SalI fragment of plasmid pHXB-2D containing the HIV-1 pol coding region was isolated and inserted into BamHI and SalI sites of pUC18. The resulting recombinant plasmid (pUC18-Dpol 1) was cut with Sst1 and dephosporylated. A synthetic double-stranded crossover linker SEQ ID NO:12 and SEQ ID NO:13! containing a Sst1 cohesive end, a BamHI site, the putative insect Spodoptera frugiperda (SF9) cell ribosome binding site (P) and 15 nucleotides of the homology searching sequences which overlaps with the 5' terminus of the pol gene was ligated at the Sst1 site and transformed. The recombinant plasmid, (pUC18-Dpol 2) was isolated, digested with sPH1, dephosphorylated and ligated with another crossover linker DNA SEQ ID NO:14 and SEQ ID NO:15! containing SphI cohesive end at the 3' terminus, BamH1 site and 15 nucleotides of the homology searching sequences which recognise the 3' terminus of the pol gene. The resulting recombinant plasmid (pUC18-Dpol 3) contains the putative SF9 cell ribosome binding site (P) followed with pol open reading frame SEQ ID NO:16! starting with the first ATG (TI) codon (map unit 2357-2359) in the pol gene and the translation termination (TT) codon TAG (map unit 5093-5095). This whole cassette was flanked with BamH1 sites. The BamH1 fragment commencing with the sequence GATCCTATAAATATG SEQ ID NO:17! and the shorter complementary sequence CATATTTATAG (listed in the 5'-3' direction) SEQ ID NO:18! was isolated and inserted into the BamH1 site of the pAcYM1 baculovirus transfer vector (pAcYM1-Dpol). The pAcYM1-Dpol transfer vector DNA was used to co-transfect SF9 cells with wild type AcNPV DNA to isolated recombinant AcNPV HIV-YK pol virus.

EXAMPLE 2

Expression of pol gene products by recombinant baculoviruses

Recombinant AcNPV-HIVWHpol contains an insert comprising essentially the whole DNA sequence of the HIV-pol gene (SEQ ID NO:19, see Table 2 at the end of the present disclosure). When expressed, the resulting full length gene product of the HIV-pol gene is "processed", i.e. the proteolytic active site of the HIV pol protease gene cleaves the protein into 66 kD, 51 kD and 32 kD fragments.

By way of comparison, recombinant AcNPV-HIVYKpol (SEQ ID NO:20, see Table 3 at the end of the present disclosure) omits NH₂ -terminal amino acid sequences of the HIV-pol gene SEQ ID NO:21! containing the proteolytic active site of the HIV-pol protease. When expressed, the resulting gene product SEQ ID NO:22! is not "processed" i.e. the ˜95 kD protein remains intact.

The following experiments illustrate this.

Uninfected S. frugiperda (SF9) cells, or SF9 cell infected with recombinant baculoviruses AcNPV-HIVWHpol, AcNPV-HIVYKpol or with wild-type AcNPV, were harvested after 72 hours of infection. Lysates of the infected or uninfected cells were electrophoresed in a 12% polyacrylamide Laemmli gel and proteins are identified by either Coomassie blue staining (S) or Western blot analyses (W) using the standard HIH HIV positive immunoglobulin. As shown in FIGS. 2aand 2b, lanes 1, 2 and 3 represents the lysates of AcNPV-HIVYHpol recombinant virus infected cells, lanes 4, 5 and 6 represent the lysates of AcNPV-HIVYKpol recombinant virus infected cells, lane 7 shows the wild-type ACNPV infected cell lysate, lane 8 shows uninfected cell lysate and lane 9 shows molecular weight markers. Lane 3 and 6 show the whole cell lysate, lanes 2 and 5 show proteins in the infected cell nuclei and lanes 1 and 4 show proteins in the infected cell cytoplasm. P denotes polyhedrin protein and arrows show 95K Dal uncleaved pol gene product representing 91 amino acid deletion of protease produced by AcNPV-HIVYKpol virus and 66K Dal, 51K Dal and 33K Dal processed pol gene products in AcNPV-HIVYHpol virus infected cells.

EXAMPLE 3

A. Production of pol gene product

Recombinant ACNPV-HIVYKpol virus infected Spodoptera frugiperda (SF9) cells were harvested 4 days after infection. Nuclei of infected cells containing most of the pol gene product were isolated by treating the infected cells with 0.1% Triton X-100 and 0.5% NP40 on ice for 20 minutes followed by centrifugation at 750 g for 10 minutes. The pelleted nuclei were denatured with 1% SDS in TRIS-HCl pH 8.0 at room temperature for 30 minutes. The cellular DNAs were removed by ethanol precipitation using 2 volumes of 100% ethanol. The SDS in the solution were removed by addition of 25 mM KCL incubated at 4° C. for 30 minutes followed by centrifugation at 12,700 g for 15 minutes. The pol gene product in the supernatant was used for anti-pol ELISA.

B. Detection of HIV antibodies by ELISA

The pol antigen was diluted in PBS and dispensed in a microtiter plate (Nunc cat 269620). The concentration of pol to coat plates was determined empirically on the strength of bands on polyacrylamide gels.

The concentration of pol necessary to coat one well was between 1 and 10 μg.

The plate was covered and incubated at 4° C. The time of incubation varied between 12 and 24 hrs without no apparent differences in reactivity.

The plates were then washed three times in PBS tween 20 employing a Skatron plate washer.

Various standards, NIH HIV+ immunoglobulin (NIH STD), pool HIV+ plasma (PAT STD) and plasma from non-infected individuals (NS) were employed. The standards were diluted beginning at 1:200 for NIH STD, and 1:10 for PAT STD and NS. Unknowns were tested usually at 1:50 but dilutions as high as 1:10 can be employed.

All samples were inactivated before testing. Normal sera were processed in the same fashion as sera from AIDS patients. The inactivation was performed with 4'-aminoethyltrioxsalen-hydrochloride (AMT) from Lee Biomolecular Research Inc. (San Diego, Calif. cat 231) and an ultra violet light trans-illuminator (Spectroline model TC-365, Fisher Scientific Ottawa Ont.). The AMT was reconstituted in 50% ethanol at 1 μg/ml. The sera was aliquoted in Eppendorf tubes and for every 100 μl of serum or plasma, 10 μl of AMT was added to the sample. The samples were layed in the transilluminator and irradiated for 5 minutes. An additional 10 μl of AMT was added to the sample and the samples were irradiated for a further 5 minutes. The samples were inactivated by this procedure.

The incubation time of the human-anti-pol was 30 to 40 minutes at room temperature (23° C.) (the time of incubation found to be quite critical). Therefore, all dilutions of standards (negative and positive) and unknowns was performed in a separate plate. Once all dilutions were done, the dilutions (100 μl) were transferred to the ELISA plate coated with pol employing a multichannel pipettor. All dilutions were with PBS Tween 20 (0.1%).

The state of the serum or plasma sample was found to be important. Samples repeatedly frozen and thawed usually gave higher backgrounds. This was especially evident with samples from normal individuals.

The plates were washed three times in PBS-Tween 20 after the 30 minute incubation with the first antibody. A Skatron II plate washer was employed for this purpose.

The second antibody used (goat anti-human Ig linked to horse radish peroxidase) was an affinity purified reagent obtained from Tago Diagnostics (Inter Medico To DNT cat 2393). An appropriate dilution was determined experimentally (approximately 1:2,000) is made in PBS-Tween 20 (0.1%). 100 μl was dispensed into the wells except for one which will be employed as a blank for the plate reader. The plate was incubated for 1 hour at room temperature.

The plates were washed three times with PBS-Tween 20 employing the Skatron II plate washer.

Freshly prepared substrate (100 μl) was added to the wells and after 20 minutes the reaction stopped with the addition of 100 μl of 0.07M H2SD4.

The plate was read at 450 nm in the BIOTEK BL/310 ELISA plate reader. A hard copy of the data was obtained from the reader and the data also stored directly onto computer diskette for further processing by the Anelisar program.

Additionally, controls were also performed on each plate. In two or three wells no serum or plasma was added. In one well no primary or secondary antibodies were added but substrate was. This well was employed to blank the ELISA plate reader. The remaining wells were employed to determine the extent of binding of the secondary antibody (Goat anti-HIg-HRPO) to POL. Thus, these wells received no primary antibody but secondary antibody and substrate with the appropriate washes in between each incubation. Usually the value of this latter control is below 0.1000 OD.

The results are shown in FIG. 3. The solid circles show the average of the results from plasma samples from five different HIV patients (N=5), and the open circles show the average of the results from the plasma from five non-infected individuals (control) at different levels of dilution. In each case, the vertical lines passing through the solid or open circles show the standard deviations of the individual results.

The following materials were use for the anti-pol ELISA procedure

Buffers

    ______________________________________     Phosphate Buffered Saline (PBS)     ______________________________________     Na.sub.2 HPO.sub.4 (dibasic anhydrous)                          13.6 g     NaH.sub.2 PO.sub.4 (monobasic)                           2.4 g     NaCl                 90.0 g     ______________________________________

Salts are dissolved in 8 litres of distilled deionized water and pH is adjusted to 7.2 with NaOH or HCl. This buffer is employed as coating buffer, diluent and washing buffer. The latter two buffers are modified as indicated below.

Diluent for primary and secondary antibodies and washing buffer

PBS+0.1% Tween 20 (Sigma, St. Louis Mo.) (0.1 ml Tween 20+100 ml PBS). The diluent buffer is made up daily.

Substrate buffer

Equal volumes of 0.1M Na₂ HPO₄ (0.709 g/50 ml) and 0.1M citric acid (0.960 g/50 ml). The pH is adjusted to 4.0 with NaOH or HCl. The substrate buffer is made up weekly.

Substrate

A tablet (2 mg) of o-phenylenediamine (Sigma cat. P6787) is dissolved into 10 ml of substrate buffer. Hydrogen peroxide (4 μl of 30%) is added to the solution just prior to plating. The solution should be kept in the dark as much as possible.

Stopping reagent

The enzymatic reaction is stopped with 0.07M H₂ SO₄.

It is a particularly advantageous feature of the polypeptides, the use of which is described herein, that they cross-react with antibodies against diverse strains of HIV. Thus, for example, the polypeptides described herein based on HIV-1 can cross-react with antibodies raised against various strains of HIV-1 and HIV-2. Thus they may be used in diagnostic kits for detecting either virus category. Similarly, in vaccines they can provide broad-spectrum protection.

Industrial Applicability

As will be apparent from the above, the present invention can be used in the medical field for testing for HIV infection and for immunizing against HIV infection, as well as for other diagnostic or prognostic purposes.

                                      TABLE 2     __________________________________________________________________________      ##STR1##      ##STR2##     2101ggccttcctacaagggaaggccagggaattttcttcagagcagaccagagccaacagccc     2161caccagaagagagcttcaggtctggggtagagacaacaactccccctcagaagcaggagc     2221cgatagacaaggaactgtatcctttaacttccctcaggtcactctttggcaacgacccct      ##STR3##     2341tacagtattagaagaaatgagtttgccaggaagatggaaaccaaaaatgatagggggaat     2401tggaggttttatcaaagtaagacagtatgatcagatactcatagaaatctgtggacataa     2461agctataggtacagtattagtaggacctacacctgtcaacataattggaagaaatctgtt     2521gactcagattggttgcactttaaattttcccattagccctattgagactgtaccagtaaa     2581attaaagccaggaatggatggcccaaaagttaaacaatggccattgacagaagaaaaaat     2641aaaagcattagtagaaatttgtacagagatggaaaaggaagggaaaatttcaaaaattgg     2701gcctgaaaatccatacaatactccagtatttgccataaagaaaaaagacagtactaaatg     2761gagaaaattagtagatttcagagaacttaataagagaactcaagacttctgggaagttca     2821attaggaataccacatcccgcagggttaaaaaagaaaaaatcagtaacagtactggatgt     2881gggtgatgcatatttttcagttcccttagatgaagacttcaggaagtatactgcatttac     2941catacctagtataaacaatgagacaccagggattagatatcagtacaatgtgcttccaca     3001gggatggaaaggatcaccagcaatattccaaagtagcatgacaaaaatcttagagccttt     3061tagaaaacaaaatccagacatagttatctatcaatacatggatgatttgtatgtaggatc     3121tgacttagaaatagggcagcatagaacaaaaatagaggagctgagacaacatctgttgag     3181gtggggacttaccacaccagacaaaaaacatcagaaagaacctccattcctttggatggg     3241ttatgaactccatcctgataaatggacagtacagcctatagtgctgccagaaaaagacag     3301ctggactgtcaatgacatacagaagttagtggggacattgaattgggcaagtcagattta     3361cccagggattaaagtaaggcaattatgtaaactccttagaggaaccaaagcactaacaga     3421agtaataccactaacagaagaagcagagctagaactggcagaaaacagagagattctaaa     3481agaaccagtacatggagtgtattatgacccatcaaaagacttaatagcagaaatacagaa     3541gcaggggcaaggccaatggacatatcaaatttatcaagagccatttaaaaatctgaaaac     3601aggaaaatatgcaagaatgaggggtgcccacactaatgatgtaaaacaattaacagaggc     3661agtgcaaaaaataaccacagaaagcatagtaatatggggaaagactcctaaatttaaact     3721gcccatacaaaaggaaacatgggaaacatggtggacagagtattggcaagccacctggat     3781tcctgagtgggagtttgttaatacccctcccttagtgaaattatggtaccagttagagaa     3841agaacccatagtaggagcagaaaccttctatgtagatggggcagctaacagggagactaa     3901attaggaaaagcaggatatgttactaatagaggaagacaaaaagttgtcaccctaactga     3961cacaacaaatcagaagactgagttacaagccatttatctagctttgcaggattcgggatt     4021agaagtaaacatagtaacagactcacaatatgcattaggaatcattcaagcacaaccaga     4081tcaaagtgaatcagagttagtcaatcaaataatagagcagttaataaaaaaggaaaaggt     4141ctatctggcatgggtaccagcacacaaaggaattggaggaaatgaacaagtagataaatt     4201agtcagtgctggaatcaggaaagtactatttttagatggaatagataaggcccaagatga     4261acatgagaaatatcacagtaattggagagcaatggctagtgattttaacctgccacctgt     4321agtagcaaaagaaatagtagccagctgtgataaatgtcagctaaaaggagaagccatgca     4381tggacaagtagactgtagtccaggaatatggcaactagattgtacacatttagaaggaaa     4441agttatcctggtagcagttcatgtagccagtggatatatagaagcagaagttattccagc     4501agaaacagggcaggaaacagcatattttcttttaaaattagcaggaagatggccagtaaa     4561aacaatacatactgacaatggcagcaatttcaccggtgctacggttagggccgcctgttg     4621gtgggcgggaatcaagcaggaatttggaattccctacaatccccaaagtcaaggagtagt     4681agaatctatgaataaagaattaaagaaaattataggacaggtaagagatcaggctgaaca     4741tcttaagacagcagtacaaatggcagtattcatccacaattttaaaagaaaaggggggat     4801tggggggtacagtgcaggggaaagaatagtagacataatagcaacagacatacaaactaa      ##STR4##      ##STR5##      ##STR6##      ##STR7##     __________________________________________________________________________

                                      TABLE 3     __________________________________________________________________________      ##STR8##      ##STR9##     2101ggccttcctacaagggaaggccagggaattttcttcagagcagaccagagccaacagccc     2161caccagaagagagcttcaggtctggggtagagacaacaactccccctcagaagcaggagc     2221cgatagacaaggaactgtatcctttaacttccctcaggtcactctttggcaacgacccct     2281cgtcacaaTAAagataggggggcaactaaaggaagctctattagatacaggagcagatga      ##STR10##     2341tacagtattagaagaaatgagtttgccaggaagatggaaaccaaaaatgatagggggaat     2401tggaggttttatcaaagtaagacagtatgatcagatactcatagaaatctgtggacataa     2461agctataggtacagtattagtaggacctacacctgtcaacataattggaagaaatctgtt     2521gactcagattggttgcactttaaattttcccattagccctattgagactgtaccagtaaa     2581attaaagccaggaatggatggcccaaaagttaaacaatggccattgacagaagaaaaaat     2641aaaagcattagtagaaatttgtacagagatggaaaaggaagggaaaatttcaaaaattgg     2701gcctgaaaatccatacaatactccagtatttgccataaagaaaaaagacagtactaaatg     2761gagaaaattagtagatttcagagaacttaataagagaactcaagacttctgggaagttca     2821attaggaataccacatcccgcagggttaaaaaagaaaaaatcagtaacagtactggatgt     2881gggtgatgcatatttttcagttcccttagatgaagacttcaggaagtatactgcatttac     2941catacctagtataaacaatgagacaccagggattagatatcagtacaatgtgcttccaca     3001gggatggaaaggatcaccagcaatattccaaagtagcatgacaaaaatcttagagccttt     3061tagaaaacaaaatccagacatagttatctatcaatacatggatgatttgtatgtaggatc     3121tgacttagaaatagggcagcatagaacaaaaatagaggagctgagacaacatctgttgag     3181gtggggacttaccacaccagacaaaaaacatcagaaagaacctccattcctttggatggg     3241ttatgaactccatcctgataaatggacagtacagcctatagtgctgccagaaaaagacag     3301ctggactgtcaatgacatacagaagttagtggggaaattgaattgggcaagtcagattta     3361cccagggattaaagtaaggcaattatgtaaactccttagaggaaccaaagcactaacaga     3421agtaataccactaacagaagaagcagagctagaactggcagaaaacagagagattctaaa     3481agaaccagtacatggagtgtattatgacccatcaaaagacttaatagcagaaatacagaa     3541gcaggggcaaggccaatggacatatcaaatttatcaagagccatttaaaaatctgaaaac     3601aggaaaatatgcaagaatgaggggtgcccacactaatgatgtaaaacaattaacagaggc     3661agtgcaaaaaataaccacagaaagcatagtaatatggggaaagactcctaaatttaaact     3721gcccatacaaaaggaaacatgggaaacatggtggacagagtattggcaagccacctggat     3781tcctgagtgggagtttgttaatacccctcccttagtgaaattatggtaccagttagagaa     3841agaacccatagtaggagcagaaaccttctatgtagatggggcagctaacagggagactaa     3901attaggaaaagcaggatatgttactaatagaggaagacaaaaagttgtcaccctaactga     3961cacaacaaatcagaagactgagttacaagcaatttatctagctttgcaggattcgggatt     4021agaagtaaacatagtaacagactcacaatatgcattaggaatcattcaagcacaaccaga     4081tcaaagtgaatcagagttagtcaatcaaataatagagcagttaataaaaaaggaaaaggt     4141ctatctggcatgggtaccagcacacaaaggaattggaggaaatgaacaagtagataaatt     4201agtcagtgctggaatcaggaaagtactatttttagatggaatagataaggcccaagatga     4261acatgagaaatatcacagtaattggagagcaatggctagtgattttaacctgccacctgt     4321agtagcaaaagaaatagtagccagctgtgataaatgtcagctaaaaggagaagccatgca     4381tggacaagtagactgtagtccaggaatatggcaactagattgtacacatttagaaggaaa     4441agttatcctggtagcagttcatgtagccagtggatatatagaagcagaagttattccagc     4501agaaacagggcaggaaacagcatattttcttttaaaattagcaggaagatggccagtaaa     4561aacaatacatactgacaatggcagcaatttcaccggtgctacggttagggccgcctgttg     4621gtgggcgggaatcaagcaggaatttggaattccctacaatccccaaagtcaaggagtagt     4681agaatctatgaataaagaattaaagaaaattataggacaggtaagagatcaggctgaaca     4741tcttaagacagcagtacaaatggcagtattcatccacaattttaaaagaaaaggggggat     4801tggggggtacagtgcaggggaaagaatagtagacataatagcaacagacatacaaactaa      ##STR11##      ##STR12##      ##STR13##      ##STR14##     5101ggaaaagtttagtaaaacaccatatgtatgtttcagggaaagctaggggatggttttata     5161gacatcactatgaaagccctcatccaagaataagttcagaagtacacatcccactagggg     5221atgctagattggtaataacaacatattggggtctgcatacaggagaaagagactggcatt     5281tgggtcagggagtctccatagaatggaggaaaaagagatatagcacacaagtagaccctg      ##STR15##     5401gaaaggccttattaggacacatagttagccctaggtgtgaatatcaagcaggacataaca      ##STR16##      ##STR17##      ##STR18##     5641tgaagctgttagacattttcctaggatttggctccatggcttagggcaacatatctatga     5701aacttatggggatacttgggcaggagtggaagccataataagaattctgcaacaactgct      ##STR19##      ##STR20##     5881cctaaaactgcttgtaccaattgctattgtaaaaagtgttgctttcattgccaagtttgt      ##STR21##      ##STR22##      ##STR23##     6121gttgtgtggtccatagtaatcatagaatataggaaaatattaagacaaagaaaaatagac     __________________________________________________________________________

    __________________________________________________________________________     SEQUENCE LISTING     (1) GENERAL INFORMATION:     (iii) NUMBER OF SEQUENCES: 22     (2) INFORMATION FOR SEQ ID NO:1:     (i) SEQUENCE CHARACTERISTICS:     (A) LENGTH: 1005 amino acids     (B) TYPE: amino acid     (C) STRANDEDNESS: Not Relevant     (D) TOPOLOGY: Not Relevant     (ii) MOLECULE TYPE: protein     (iii) HYPOTHETICAL: NO     (v) FRAGMENT TYPE: internal     (vi) ORIGINAL SOURCE:     (A) ORGANISM: Human immunodeficiency virus type 1     (B) STRAIN: HXB2     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:     MetPhePheArgGluAspLeuAlaPheLeuGlnGlyLysAlaArgGlu     151015     PheSerSerGluGlnThrArgAlaAsnSerProThrArgArgGluLeu     202530     GlnValTrpGlyArgAspAsnAsnSerProSerGluAlaGlyAlaAsp     354045     ArgGlnGlyThrValSerPheAsnPheProGlnValThrLeuTrpGln     505560     ArgProLeuValThrIleLysIleGlyGlyGlnLeuLysGluAlaLeu     65707580     LeuAspThrGlyAlaAspAspThrValLeuGluGluMetSerLeuPro     859095     GlyArgTrpLysProLysMetIleGlyGlyIleGlyGlyPheIleLys     100105110     ValArgGlnTyrAspGlnIleLeuIleGluIleCysGlyHisLysAla     115120125     IleGlyThrValLeuValGlyProThrProValAsnIleIleGlyArg     130135140     AsnLeuLeuThrGlnIleGlyCysThrLeuAsnPheProIleSerPro     145150155160     IleGluThrValProValLysLeuLysProGlyMetAspGlyProLys     165170175     ValLysGlnTrpProLeuThrGluGluLysIleLysAlaLeuValGlu     180185190     IleCysThrGluMetGluLysGluGlyLysIleSerLysIleGlyPro     195200205     GluAsnProTyrAsnThrProValPheAlaIleLysLysLysAspSer     210215220     ThrLysTrpArgLysLeuValAspPheArgGluLeuAsnLysArgThr     225230235240     GlnAspPheTrpGluValGlnLeuGlyIleProHisProAlaGlyLeu     245250255     LysLysLysLysSerValThrValLeuAspValGlyAspAlaTyrPhe     260265270     SerValProLeuAspGluAspPheArgLysTyrThrAlaPheThrIle     275280285     ProSerIleAsnAsnGluThrProGlyIleArgTyrGlnTyrAsnVal     290295300     LeuProGlnGlyTrpLysGlySerProAlaIlePheGlnSerSerMet     305310315320     ThrLysIleLeuGluProPheArgLysGlnAsnProAspIleValIle     325330335     TyrGlnTyrMetAspAspLeuTyrValGlySerAspLeuGluIleGly     340345350     GlnHisArgThrLysIleGluGluLeuArgGlnHisLeuLeuArgTrp     355360365     GlyLeuThrThrProAspLysLysHisGlnLysGluProProPheLeu     370375380     TrpMetGlyTyrGluLeuHisProAspLysTrpThrValGlnProIle     385390395400     ValLeuProGluLysAspSerTrpThrValAsnAspIleGlnLysLeu     405410415     ValGlyLysLeuAsnTrpAlaSerGlnIleTyrProGlyIleLysVal     420425430     ArgGlnLeuCysLysLeuLeuArgGlyThrLysAlaLeuThrGluVal     435440445     IleProLeuThrGluGluAlaGluLeuGluLeuAlaGluAsnArgGlu     450455460     IleLeuLysGluProValHisGlyValTyrTyrAspProSerLysAsp     465470475480     LeuIleAlaGluIleGlnLysGlnGlyGlnGlyGlnTrpThrTyrGln     485490495     IleTyrGlnGluProPheLysAsnLeuLysThrGlyLysTyrAlaArg     500505510     MetArgGlyAlaHisThrAsnAspValLysGlnLeuThrGluAlaVal     515520525     GlnLysIleThrThrGluSerIleValIleTrpGlyLysThrProLys     530535540     PheLysLeuProIleGlnLysGluThrTrpGluThrTrpTrpThrGlu     545550555560     TyrTrpGlnAlaThrTrpIleProGluTrpGluPheValAsnThrPro     565570575     ProLeuValLysLeuTrpTyrGlnLeuGluLysGluProIleValGly     580585590     AlaGluThrPheTyrValAspGlyAlaAlaAsnArgGluThrLysLeu     595600605     GlyLysAlaGlyTyrValThrAsnArgGlyArgGlnLysValValThr     610615620     LeuThrAspThrThrAsnGlnLysThrGluLeuGlnAlaIleTyrLeu     625630635640     AlaLeuGlnAspSerGlyLeuGluValAsnIleValThrAspSerGln     645650655     TyrAlaLeuGlyIleIleGlnAlaGlnProAspGlnSerGluSerGlu     660665670     LeuValAsnGlnIleIleGluGlnLeuIleLysLysGluLysValTyr     675680685     LeuAlaTrpValProAlaHisLysGlyIleGlyGlyAsnGluGlnVal     690695700     AspLysLeuValSerAlaGlyIleArgLysValLeuPheLeuAspGly     705710715720     IleAspLysAlaGlnAspGluHisGluLysTyrHisSerAsnTrpArg     725730735     AlaMetAlaSerAspPheAsnLeuProProValValAlaLysGluIle     740745750     ValAlaSerCysAspLysCysGlnLeuLysGlyGluAlaMetHisGly     755760765     GlnValAspCysSerProGlyIleTrpGlnLeuAspCysThrHisLeu     770775780     GluGlyLysValIleLeuValAlaValHisValAlaSerGlyTyrIle     785790795800     GluAlaGluValIleProAlaGluThrGlyGlnGluThrAlaTyrPhe     805810815     LeuLeuLysLeuAlaGlyArgTrpProValLysThrIleHisThrAsp     820825830     AsnGlySerAsnPheThrGlyAlaThrValArgAlaAlaCysTrpTrp     835840845     AlaGlyIleLysGlnGluPheGlyIleProTyrAsnProGlnSerGln     850855860     GlyValValGluSerMetAsnLysGluLeuLysLysIleIleGlyGln     865870875880     ValArgAspGlnAlaGluHisLeuLysThrAlaValGlnMetAlaVal     885890895     PheIleHisAsnPheLysArgLysGlyGlyIleGlyGlyTyrSerAla     900905910     GlyGluArgIleValAspIleIleAlaThrAspIleGlnThrLysGlu     915920925     LeuGlnLysGlnIleThrLysIleGlnAsnPheArgValTyrTyrArg     930935940     AspSerArgAsnSerLeuTrpLysGlyProAlaLysLeuLeuTrpLys     945950955960     GlyGluGlyAlaValValIleGlnAspAsnSerAspIleLysValVal     965970975     ProArgArgLysAlaLysIleIleArgAspTyrGlyLysGlnMetAla     980985990     GlyAspAspCysValAlaSerArgGlnAspGluAspXaa     99510001005     (2) INFORMATION FOR SEQ ID NO:2:     (i) SEQUENCE CHARACTERISTICS:     (A) LENGTH: 1016 amino acids     (B) TYPE: amino acid     (C) STRANDEDNESS: Not Relevant     (D) TOPOLOGY: Not Relevant     (ii) MOLECULE TYPE: protein     (iii) HYPOTHETICAL: NO     (v) FRAGMENT TYPE: internal     (vi) ORIGINAL SOURCE:     (A) ORGANISM: Human immunodeficiency virus type 1     (B) STRAIN: BH102     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:     PhePheArgGluAspLeuAlaPheLeuGlnGlyLysAlaArgGluPhe     151015     SerSerGluGlnThrArgAlaAsnSerProThrIleSerSerGluGln     202530     ThrArgAlaAsnSerProThrArgArgGluLeuGlnValTrpGlyArg     354045     AspAsnAsnSerProSerGluAlaGlyAlaAspArgGlnGlyThrVal     505560     SerPheAsnPheProGlnIleThrLeuTrpGlnArgProLeuValThr     65707580     IleLysIleGlyGlyGlnLeuLysGluAlaLeuLeuAspThrGlyAla     859095     AspAspThrValLeuGluGluMetSerLeuProGlyArgTrpLysPro     100105110     LysMetIleGlyGlyIleGlyGlyPheIleLysValArgGlnTyrAsp     115120125     GlnIleLeuIleGluIleCysGlyHisLysAlaIleGlyThrValLeu     130135140     ValGlyProThrProValAsnIleIleGlyArgAsnLeuLeuThrGln     145150155160     IleGlyCysThrLeuAsnPheProIleSerProIleGluThrValPro     165170175     ValLysLeuLysProGlyMetAspGlyProLysValLysGlnTrpPro     180185190     LeuThrGluGluLysIleLysAlaLeuValGluIleCysThrGluMet     195200205     GluLysGluGlyLysIleSerLysIleGlyProGluAsnProTyrAsn     210215220     ThrProValPheAlaIleLysLysLysAspSerThrLysTrpArgLys     225230235240     LeuValAspPheArgGluLeuAsnLysArgThrGlnAspPheTrpGlu     245250255     ValGlnLeuGlyIleProHisProAlaGlyLeuLysLysLysLysSer     260265270     ValThrValLeuAspValGlyAspAlaTyrPheSerValProLeuAsp     275280285     GluAspPheArgLysTyrThrAlaPheThrIleProSerIleAsnAsn     290295300     GluThrProGlyIleArgTyrGlnTyrAsnValLeuProGlnGlyTrp     305310315320     LysGlySerProAlaIlePheGlnSerSerMetThrLysIleLeuGlu     325330335     ProPheLysLysGlnAsnProAspIleValIleTyrGlnTyrMetAsp     340345350     AspLeuTyrValGlySerAspLeuGluIleGlyGlnHisArgThrLys     355360365     IleGluGluLeuArgGlnHisLeuLeuArgTrpGlyLeuThrThrPro     370375380     AspLysLysHisGlnLysGluProProPheLeuTrpMetGlyTyrGlu     385390395400     LeuHisProAspLysTrpThrValGlnProIleValLeuProGluLys     405410415     AspSerTrpThrValAsnAspIleGlnLysLeuValGlyLysLeuAsn     420425430     TrpAlaSerGlnIleTyrProGlyIleLysValArgGlnLeuCysLys     435440445     LeuLeuArgGlyThrLysAlaLeuThrGluValIleProLeuThrGlu     450455460     GluAlaGluLeuGluLeuAlaGluAsnArgGluIleLeuLysGluPro     465470475480     ValHisGlyValTyrTyrAspProSerLysAspLeuIleAlaGluIle     485490495     GlnLysGlnGlyGlnGlyGlnTrpThrTyrGlnIleTyrGlnGluPro     500505510     PheLysAsnLeuLysThrGlyLysTyrAlaArgMetArgGlyAlaHis     515520525     ThrAsnAspValLysGlnLeuThrGluAlaValGlnLysIleThrThr     530535540     GluSerIleValIleTrpGlyLysThrProLysPheLysLeuProIle     545550555560     GlnLysGluThrTrpGluThrTrpTrpThrGluTyrTrpGlnAlaThr     565570575     TrpIleProGluTrpGluPheValAsnThrProProLeuValLysLeu     580585590     TrpTyrGlnLeuGluLysGluProIleValGlyAlaGluThrPheTyr     595600605     ValAspGlyAlaAlaAsnArgGluThrLysLeuGlyLysAlaGlyTyr     610615620     ValThrAsnLysGlyArgGlnLysValValProLeuThrAsnThrThr     625630635640     AsnGlnLysThrGluLeuGlnAlaIleTyrLeuAlaLeuGlnAspSer     645650655     GlyLeuGluValAsnIleValThrAspSerGlnTyrAlaLeuGlyIle     660665670     IleGlnAlaGlnProAspLysSerGluSerGluLeuValAsnGlnIle     675680685     IleGluGlnLeuIleLysLysGluLysValTyrLeuAlaTrpValPro     690695700     AlaHisLysGlyIleGlyGlyAsnGluGlnValAspLysLeuValSer     705710715720     AlaGlyIleArgLysIleLeuPheLeuAspGlyIleAspLysAlaGln     725730735     AspGluHisGluLysTyrHisSerAsnTrpArgAlaMetAlaSerAsp     740745750     PheAsnLeuProProValValAlaLysGluIleValAlaSerCysAsp     755760765     LysCysGlnLeuLysGlyGluAlaMetHisGlyGlnValAspCysSer     770775780     ProGlyIleTrpGlnLeuAspCysThrHisLeuGluGlyLysValIle     785790795800     LeuValAlaValHisValAlaSerGlyTyrIleGluAlaGluValIle     805810815     ProAlaGluThrGlyGlnGluThrAlaTyrPheLeuLeuLysLeuAla     820825830     GlyArgTrpProValLysThrIleHisThrAspAsnGlySerAsnPhe     835840845     ThrSerAlaThrValLysAlaAlaCysTrpTrpAlaGlyIleLysGln     850855860     GluPheGlyIleProTyrAsnProGlnSerGlnGlyValValGluSer     865870875880     MetAsnLysGluLeuLysLysIleIleGlyGlnValArgAspGlnAla     885890895     GluHisLeuLysThrAlaValGlnMetAlaValPheIleHisAsnPhe     900905910     LysArgLysGlyGlyIleGlyGlyTyrSerAlaGlyGluArgIleVal     915920925     AspIleIleAlaThrAspIleGlnThrLysGluLeuGlnLysGlnIle     930935940     ThrLysIleGlnAsnPheArgValTyrTyrArgAspSerArgAsnPro     945950955960     LeuTrpLysGlyProAlaLysLeuLeuTrpLysGlyGluGlyAlaVal     965970975     ValIleGlnAspAsnSerAspIleLysValValProArgArgLysAla     980985990     LysIleIleArgAspTyrGlyLysGlnMetAlaGlyAspAspCysVal     99510001005     AlaSerArgGlnAspGluAspXaa     10101015     (2) INFORMATION FOR SEQ ID NO:3:     (i) SEQUENCE CHARACTERISTICS:     (A) LENGTH: 1016 amino acids     (B) TYPE: amino acid     (C) STRANDEDNESS: Not Relevant     (D) TOPOLOGY: Not Relevant     (ii) MOLECULE TYPE: protein     (iii) HYPOTHETICAL: NO     (v) FRAGMENT TYPE: internal     (vi) ORIGINAL SOURCE:     (A) ORGANISM: Human immunodeficiency virus type 1     (B) STRAIN: BH5     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:     PhePheArgGluAspLeuAlaPheLeuGlnGlyLysAlaArgGluPhe     151015     SerSerGluGlnThrArgAlaAsnSerProThrIleSerSerGluGln     202530     ThrArgAlaAsnSerProThrArgArgGluLeuGlnValTrpGlyArg     354045     AspAsnAsnSerProSerGluAlaGlyAlaAspArgGlnGlyThrVal     505560     SerPheAsnPheProGlnIleThrLeuTrpGlnArgProLeuValThr     65707580     IleLysIleGlyGlyGlnLeuLysGluAlaLeuLeuAspThrGlyAla     859095     AspAspThrValLeuGluGluMetSerLeuProGlyArgTrpLysPro     100105110     LysMetIleGlyGlyIleGlyGlyPheIleLysValArgGlnTyrAsp     115120125     GlnIleLeuIleGluIleCysGlyHisLysAlaIleGlyThrValLeu     130135140     ValGlyProThrProValAsnIleIleGlyArgAsnLeuLeuThrGln     145150155160     IleGlyCysThrLeuAsnPheProIleSerProIleGluThrValPro     165170175     ValLysLeuLysProGlyMetAspGlyProLysValLysGlnTrpPro     180185190     LeuThrGluGluLysIleLysAlaLeuValGluIleCysThrGluMet     195200205     GluLysGluGlyLysIleSerLysIleGlyProGluAsnProTyrAsn     210215220     ThrProValPheAlaIleLysLysLysAspSerThrLysTrpArgLys     225230235240     LeuValAspPheArgGluLeuAsnArgArgThrGlnAspPheTrpGlu     245250255     ValGlnLeuGlyIleProHisProAlaGlyLeuLysLysLysLysSer     260265270     ValThrValLeuAspValGlyAspAlaTyrPheSerValProLeuAsp     275280285     GluAspPheArgLysTyrThrAlaPheThrIleProSerIleAsnAsn     290295300     GluThrProGlySerGlyTyrGlnTyrAsnValLeuProGlnGlyTrp     305310315320     LysGlySerProAlaIlePheGlnSerSerMetThrLysIleLeuGlu     325330335     ProPheArgLysGlnAsnProAspIleValIleTyrGlnTyrMetAsp     340345350     AspLeuTyrValGlySerAspLeuGluIleGlyGlnHisArgThrLys     355360365     IleGluGluLeuArgGlnHisLeuLeuArgTrpGlyPheThrThrPro     370375380     AspLysLysHisGlnLysGluProProPheLeuTrpMetGlyTyrGlu     385390395400     LeuHisProAspLysTrpThrIleGlnProIleValLeuProGluLys     405410415     AspSerTrpThrValAsnAspIleGlnLysLeuValGlyLysLeuAsn     420425430     TrpAlaSerGlnIleTyrProGlyIleLysValArgGlnLeuCysLys     435440445     LeuLeuArgGlyThrLysAlaLeuThrGluValIleProLeuThrGlu     450455460     GluAlaGluLeuGluLeuAlaGluAsnArgGluIleLeuLysGluPro     465470475480     ValHisGlyValTyrTyrAspProSerLysAspLeuIleAlaGluIle     485490495     GlnLysGlnGlyGlnGlyGlnTrpThrTyrGlnIleTyrGlnGluPro     500505510     PheLysAsnLeuLysThrGlyLysTyrAlaArgMetArgGlyAlaHis     515520525     ThrAsnAspValLysGlnLeuThrGluAlaValGlnLysIleThrThr     530535540     GluSerIleValIleTrpGlyLysThrProLysPheLysLeuProIle     545550555560     GlnLysGluThrTrpGluThrTrpTrpThrGluTyrTrpGlnAlaThr     565570575     TrpIleProGluTrpGluPheValAsnThrProProLeuValLysLeu     580585590     TrpTyrGlnLeuGluLysGluProIleValGlyAlaGluThrPheTyr     595600605     ValAspGlyAlaAlaSerArgGluThrLysLeuGlyLysAlaGlyTyr     610615620     ValThrAsnArgGlyArgGlnLysValValThrLeuThrHisThrThr     625630635640     AsnGlnLysThrGluLeuGlnAlaIleHisLeuAlaLeuGlnAspSer     645650655     GlyLeuGluValAsnIleValThrAspSerGlnTyrAlaLeuGlyIle     660665670     IleGlnAlaGlnProAspLysSerGluSerGluLeuValAsnGlnIle     675680685     IleGluGlnLeuIleLysLysGluLysValTyrLeuAlaTrpValPro     690695700     AlaHisLysGlyIleGlyGlyAsnGluGlnValAspLysLeuValSer     705710715720     AlaGlyIleArgLysIleLeuPheLeuAspGlyIleAspLysAlaGln     725730735     GluGluHisGluLysTyrHisSerAsnTrpArgAlaMetAlaSerAsp     740745750     PheAsnLeuProProValValAlaLysGluIleValAlaSerCysAsp     755760765     LysCysGlnLeuLysGlyGluAlaMetHisGlyGlnValAspCysSer     770775780     ProGlyIleTrpGlnLeuAspCysThrHisLeuGluGlyLysValIle     785790795800     LeuValAlaValHisValAlaSerGlyTyrIleGluAlaGluValIle     805810815     ProAlaGluThrGlyGlnGluThrAlaTyrPheLeuLeuLysLeuAla     820825830     GlyArgTrpProValLysThrIleHisThrAspAsnGlySerAsnPhe     835840845     ThrSerAlaThrValLysAlaAlaCysTrpTrpAlaGlyIleLysGln     850855860     GluPheGlyIleProTyrAsnProGlnSerGlnGlyValValGluSer     865870875880     MetAsnLysGluLeuLysLysIleIleGlyGlnValArgAspGlnAla     885890895     GluHisLeuLysThrAlaValGlnMetAlaValPheIleHisAsnPhe     900905910     LysArgLysGlyGlyIleGlyGlyTyrSerAlaGlyGluArgIleVal     915920925     AspIleIleAlaThrAspIleGlnThrLysGluLeuGlnLysGlnIle     930935940     ThrLysIleGlnAsnPheArgValTyrTyrArgAspSerArgAsnPro     945950955960     LeuTrpLysGlyProAlaLysLeuLeuTrpLysGlyGluGlyAlaVal     965970975     ValIleGlnAspAsnSerAspIleLysValValProArgArgLysAla     980985990     LysIleIleArgAspTyrGlyLysGlnMetAlaGlyAspAspCysVal     99510001005     AlaSerArgGlnAspGluAspXaa     10101015     (2) INFORMATION FOR SEQ ID NO:4:     (i) SEQUENCE CHARACTERISTICS:     (A) LENGTH: 1016 amino acids     (B) TYPE: amino acid     (C) STRANDEDNESS: Not Relevant     (D) TOPOLOGY: Not Relevant     (ii) MOLECULE TYPE: protein     (iii) HYPOTHETICAL: NO     (v) FRAGMENT TYPE: internal     (vi) ORIGINAL SOURCE:     (A) ORGANISM: Human immunodeficiency virus type 1     (B) STRAIN: PV22     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:     PhePheArgGluAspLeuAlaPheLeuGlnGlyLysAlaArgGluPhe     151015     SerSerGluGlnThrArgAlaAsnSerProThrIleSerSerGluGln     202530     ThrArgAlaAsnSerProThrArgArgGluLeuGlnValTrpGlyArg     354045     AspAsnAsnSerProSerGluAlaGlyAlaAspArgGlnGlyThrVal     505560     SerPheAsnPheProGlnIleThrLeuTrpGlnArgProLeuValThr     65707580     IleLysIleGlyGlyGlnLeuLysGluAlaLeuLeuAspThrGlyAla     859095     AspAspThrValLeuGluGluMetSerLeuProGlyArgTrpLysPro     100105110     LysMetIleGlyGlyIleGlyGlyPheIleLysValArgGlnTyrAsp     115120125     GlnIleLeuIleGluIleCysGlyHisLysAlaIleGlyThrValLeu     130135140     ValGlyProThrProValAsnIleIleGlyArgAsnLeuLeuThrGln     145150155160     IleGlyCysThrLeuAsnPheProIleSerProIleGluThrValPro     165170175     ValLysLeuLysProGlyMetAspGlyProLysValLysGlnTrpPro     180185190     LeuThrGluGluLysIleLysAlaLeuValGluIleCysThrGluMet     195200205     GluLysGluGlyLysIleSerLysIleGlyProGluAsnProTyrAsn     210215220     ThrProValPheAlaIleLysLysLysAspSerThrLysTrpArgLys     225230235240     LeuValAspPheArgGluLeuAsnLysArgThrGlnAspPheTrpGlu     245250255     ValGlnLeuGlyIleProHisProAlaGlyLeuLysLysLysLysSer     260265270     ValThrValLeuAspValGlyAspAlaTyrPheSerValProLeuAsp     275280285     GluAspPheArgLysTyrThrAlaPheThrIleProSerIleAsnAsn     290295300     GluThrProGlyIleArgTyrGlnTyrAsnValLeuProGlnGlyTrp     305310315320     LysGlySerProAlaIlePheGlnSerSerMetThrLysIleLeuGlu     325330335     ProPheArgLysGlnAsnProAspIleValIleTyrGlnTyrMetAsp     340345350     AspLeuTyrValGlySerAspLeuGluIleGlyGlnHisArgThrLys     355360365     IleGluGluLeuArgGlnHisLeuLeuArgTrpGlyLeuThrThrPro     370375380     AspLysLysHisGlnLysGluProProPheLeuTrpMetGlyTyrGlu     385390395400     LeuHisProAspLysTrpThrValGlnProIleValLeuProGluLys     405410415     AspSerTrpThrValAsnAspIleGlnLysLeuValGlyLysLeuAsn     420425430     TrpAlaSerGlnIleTyrProGlyIleLysValArgGlnLeuCysLys     435440445     LeuLeuArgGlyThrLysAlaLeuThrGluValIleProLeuThrGlu     450455460     GluAlaGluLeuGluLeuAlaGluAsnArgGluIleLeuLysGluPro     465470475480     ValHisGlyValTyrTyrAspProSerLysAspLeuIleAlaGluIle     485490495     GlnLysGlnGlyGlnGlyGlnTrpThrTyrGlnIleTyrGlnGluPro     500505510     PheLysAsnLeuLysThrGlyLysTyrAlaArgMetArgGlyAlaHis     515520525     ThrAsnAspValLysGlnLeuThrGluAlaValGlnLysIleThrThr     530535540     GluSerIleValIleTrpGlyLysThrProLysPheLysLeuProIle     545550555560     GlnLysGluThrTrpGluThrTrpTrpThrGluTyrTrpGlnAlaThr     565570575     TrpIleProGluTrpGluPheValAsnThrProProLeuValLysLeu     580585590     TrpTyrGlnLeuGluLysGluProIleValGlyAlaGluThrPheTyr     595600605     ValAspGlyAlaAlaAsnArgGluThrArgLeuGlyLysAlaGlyTyr     610615620     LeuThrAsnLysGlyArgGlnLysValValProLeuThrAsnThrThr     625630635640     AsnGlnLysThrGluLeuGlnAlaIleTyrLeuAlaLeuGlnAspSer     645650655     GlyLeuGluValAsnIleValThrAspSerGlnTyrAlaLeuGlyIle     660665670     IleGlnAlaGlnProAspGlnSerGluSerGluLeuValAsnGlnIle     675680685     IleGluGlnLeuIleLysLysGlnLysValTyrLeuAlaTrpValPro     690695700     AlaHisLysGlyIleGlyGlyAsnGluGlnValAspLysLeuValSer     705710715720     AlaGlyIleArgLysIleLeuPheLeuAspGlyIleAspLysAlaGln     725730735     AspGluHisGluLysTyrHisSerAsnTrpArgAlaMetAlaSerAsp     740745750     PheAsnLeuProProValValAlaLysGluIleValAlaSerCysAsp     755760765     LysCysGlnLeuLysGlyGluAlaMetHisGlyGlnValAspCysSer     770775780     ProGlyIleTrpGlnLeuAspCysThrHisLeuGluGlyLysValIle     785790795800     LeuValAlaValHisValAlaSerGlyTyrIleGluAlaGluValIle     805810815     ProAlaGluThrGlyGlnGluThrAlaTyrPheLeuLeuLysLeuAla     820825830     GlyArgTrpProValLysThrIleHisThrAspAsnGlySerAsnPhe     835840845     ThrSerAlaThrValLysAlaAlaCysTrpTrpAlaGlyIleLysGln     850855860     GluPheGlyIleProTyrAsnProGlnSerGlnGlyValValGluSer     865870875880     MetAsnLysGluLeuLysLysIleIleGlyGlnValArgAspGlnAla     885890895     GluHisLeuLysThrAlaValGlnMetAlaValPheIleHisAsnPhe     900905910     LysArgLysGlyGlyIleGlyGlyTyrSerAlaGlyGluArgIleVal     915920925     AspIleIleAlaThrAspIleGlnThrLysGluLeuGlnLysGlnIle     930935940     ThrLysIleGlnAsnPheArgValTyrTyrArgAspSerArgAsnPro     945950955960     LeuTrpLysGlyProAlaLysLeuLeuTrpLysGlyGluGlyAlaVal     965970975     ValIleGlnAspAsnSerAspIleLysValValProArgArgLysAla     980985990     LysIleIleArgAspTyrGlyLysGlnMetAlaGlyAspAspCysVal     99510001005     AlaSerArgGlnAspGluAspXaa     10101015     (2) INFORMATION FOR SEQ ID NO:5:     (i) SEQUENCE CHARACTERISTICS:     (A) LENGTH: 1016 amino acids     (B) TYPE: amino acid     (C) STRANDEDNESS: Not Relevant     (D) TOPOLOGY: Not Relevant     (ii) MOLECULE TYPE: protein     (iii) HYPOTHETICAL: NO     (v) FRAGMENT TYPE: internal     (vi) ORIGINAL SOURCE:     (A) ORGANISM: Human immunodeficiency virus type 1     (B) STRAIN: BRU     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:     PhePheArgGluAspLeuAlaPheLeuGlnGlyLysAlaArgGluPhe     151015     SerSerGluGlnThrArgAlaAsnSerProThrIleSerSerGluGln     202530     ThrArgAlaAsnSerProThrArgArgGluLeuGlnValTrpGlyArg     354045     AspAsnAsnSerLeuSerGluAlaGlyAlaAspArgGlnGlyThrVal     505560     SerPheAsnPheProGlnIleThrLeuTrpGlnArgProLeuValThr     65707580     IleLysIleGlyGlyGlnLeuLysGluAlaLeuLeuAspThrGlyAla     859095     AspAspThrValLeuGluGluMetSerLeuProGlyArgTrpLysPro     100105110     LysMetIleGlyGlyIleGlyGlyPheIleLysValArgGlnTyrAsp     115120125     GlnIleLeuIleGluIleCysGlyHisLysAlaIleGlyThrValLeu     130135140     ValGlyProThrProValAsnIleIleGlyArgAsnLeuLeuThrGln     145150155160     IleGlyCysThrLeuAsnPheProIleSerProIleGluThrValPro     165170175     ValLysLeuLysProGlyMetAspGlyProLysValLysGlnTrpPro     180185190     LeuThrGluGluLysIleLysAlaLeuValGluIleCysThrGluMet     195200205     GluLysGluGlyLysIleSerLysIleGlyProGluAsnProTyrAsn     210215220     ThrProValPheAlaIleLysLysLysAspSerThrLysTrpArgLys     225230235240     LeuValAspPheArgGluLeuAsnLysArgThrGlnAspPheTrpGlu     245250255     ValGlnLeuGlyIleProHisProAlaGlyLeuLysLysLysLysSer     260265270     ValThrValLeuAspValGlyAspAlaTyrPheSerValProLeuAsp     275280285     GluAspPheArgLysTyrThrAlaPheThrIleProSerIleAsnAsn     290295300     GluThrProGlyIleArgTyrGlnTyrAsnValLeuProGlnGlyTrp     305310315320     LysGlySerProAlaIlePheGlnSerSerMetThrLysIleLeuGlu     325330335     ProPheArgLysGlnAsnProAspIleValIleTyrGlnTyrMetAsp     340345350     AspLeuTyrValGlySerAspLeuGluIleGlyGlnHisArgThrLys     355360365     IleGluGluLeuArgGlnHisLeuLeuArgTrpGlyLeuThrThrPro     370375380     AspLysLysHisGlnLysGluProProPheLeuTrpMetGlyTyrGlu     385390395400     LeuHisProAspLysTrpThrValGlnProIleValLeuProGluLys     405410415     AspSerTrpThrValAsnAspIleGlnLysLeuValGlyLysLeuAsn     420425430     TrpAlaSerGlnIleTyrProGlyIleLysValArgGlnLeuCysLys     435440445     LeuLeuArgGlyThrLysAlaLeuThrGluValIleProLeuThrGlu     450455460     GluAlaGluLeuGluLeuAlaGluAsnArgGluIleLeuLysGluPro     465470475480     ValHisGlyValTyrTyrAspProSerLysAspLeuIleAlaGluIle     485490495     GlnLysGlnGlyGlnGlyGlnTrpThrTyrGlnIleTyrGlnGluPro     500505510     PheLysAsnLeuLysThrGlyLysTyrAlaArgThrArgGlyAlaHis     515520525     ThrAsnAspValLysGlnLeuThrGluAlaValGlnLysIleThrThr     530535540     GluSerIleValIleTrpGlyLysThrProLysPheLysLeuProIle     545550555560     GlnLysGluThrTrpGluThrTrpTrpThrGluTyrTrpGlnAlaThr     565570575     TrpIleProGluTrpGluPheValAsnThrProProLeuValLysLeu     580585590     TrpTyrGlnLeuGluLysGluProIleValGlyAlaGluThrPheTyr     595600605     ValAspGlyAlaAlaSerArgGluThrLysLeuGlyLysAlaGlyTyr     610615620     LeuThrAsnLysGlyArgGlnLysValValThrLeuThrAspThrThr     625630635640     AsnGlnLysThrGluLeuGlnAlaIleHisLeuAlaLeuGlnAspSer     645650655     GlyLeuGluValAsnIleValThrAspSerGlnTyrAlaLeuGlyIle     660665670     IleGlnAlaGlnProAspLysSerGluSerGluLeuValAsnGlnIle     675680685     IleGluGlnLeuIleLysLysGluLysValTyrLeuAlaTrpValPro     690695700     AlaHisLysGlyIleGlyGlyAsnGluGlnValAspLysLeuValSer     705710715720     AlaGlyIleArgLysIleLeuPheLeuAspGlyIleAspLysAlaGln     725730735     AspGluHisGluLysTyrHisSerAsnTrpArgAlaMetAlaSerAsp     740745750     PheAsnLeuProProValValAlaLysGluIleValAlaSerCysAsp     755760765     LysCysGlnLeuLysGlyGluAlaMetHisGlyGlnValAspCysSer     770775780     ProGlyIleTrpGlnLeuAspCysThrHisLeuGluGlyLysValIle     785790795800     LeuValAlaValHisValAlaSerGlyTyrIleGluAlaGluValIle     805810815     ProAlaGluThrGlyGlnGluThrAlaTyrPheLeuLeuLysLeuAla     820825830     GlyArgTrpProValLysThrIleHisThrAspAsnGlySerAsnPhe     835840845     ThrSerThrThrValLysAlaAlaCysTrpTrpAlaGlyIleLysGln     850855860     GluPheGlyIleProTyrAsnProGlnSerGlnGlyValValGluSer     865870875880     MetAsnLysGluLeuLysLysIleIleGlyGlnValArgAspGlnAla     885890895     GluHisLeuLysThrAlaValGlnMetAlaValPheIleHisAsnPhe     900905910     LysArgLysGlyGlyIleGlyGlyTyrSerAlaGlyGluArgIleVal     915920925     AspIleIleAlaThrAspIleGlnThrLysGluLeuGlnLysGlnIle     930935940     ThrLysIleGlnAsnPheArgValTyrTyrArgAspSerArgAspPro     945950955960     LeuTrpLysGlyProAlaLysLeuLeuTrpLysGlyGluGlyAlaVal     965970975     ValIleGlnAspAsnSerAspIleLysValValProArgArgLysAla     980985990     LysIleIleArgAspTyrGlyLysGlnMetAlaGlyAspAspCysVal     99510001005     AlaSerArgGlnAspGluAspXaa     10101015     (2) INFORMATION FOR SEQ ID NO:6:     (i) SEQUENCE CHARACTERISTICS:     (A) LENGTH: 913 amino acids     (B) TYPE: amino acid     (C) STRANDEDNESS: Not Relevant     (D) TOPOLOGY: Not Relevant     (ii) MOLECULE TYPE: protein     (iii) HYPOTHETICAL: NO     (v) FRAGMENT TYPE: internal     (vi) ORIGINAL SOURCE:     (A) ORGANISM: Human immunodeficiency virus type 1     (B) STRAIN: MN     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:     MetAsnLeuProArgArgTrpLysProLysMetIleGlyGlyIleGly     151015     GlyPheIleLysValArgGlnTyrAspGlnIleThrIleGlyIleCys     202530     GlyHisLysAlaIleGlyThrValLeuValGlyProThrProValAsn     354045     IleIleGlyArgAsnLeuLeuThrGlnLeuGlyCysThrLeuAsnPhe     505560     ProIleSerProIleGluThrValProValLysLeuLysProGlyMet     65707580     AspGlyProLysValLysGlnTrpProLeuThrGluGluLysIleLys     859095     AlaLeuIleGluIleCysThrGluMetGluLysGluGlyLysIleSer     100105110     LysIleGlyProGluAsnProTyrAsnThrProValPheAlaIleLys     115120125     LysLysAspSerThrLysTrpArgLysLeuValAspPheArgGluLeu     130135140     AsnLysLysThrGlnAspPheTrpGluValGlnLeuGlyIleProHis     145150155160     ProAlaGlyLeuLysLysLysLysSerValThrValLeuAspValGly     165170175     AspAlaTyrPheSerValProLeuAspLysAspPheArgLysTyrThr     180185190     AlaPheThrIleProSerIleAsnAsnGluThrProGlyIleArgTyr     195200205     GlnTyrAsnValLeuProGlnGlyTrpLysGlySerProAlaIlePhe     210215220     GlnSerSerMetThrLysIleLeuGluProPheArgLysGlnAsnPro     225230235240     AspIleValIleTyrGlnTyrMetAspAspLeuTyrValGlySerAsp     245250255     LeuGluIleGlyGlnHisArgAlaLysIleGluGluLeuArgArgHis     260265270     LeuLeuArgTrpGlyPheThrThrProAspLysLysHisGlnLysGlu     275280285     ProProPheLeuTrpMetGlyTyrGluLeuHisProAspLysTrpThr     290295300     ValGlnProIleValLeuProGluLysAspSerTrpThrValAsnAsp     305310315320     IleGlnLysLeuValGlyLysLeuAsnTrpAlaSerGlnIleTyrAla     325330335     GlyIleLysValLysGlnLeuCysLysLeuLeuArgGlyThrLysAla     340345350     LeuThrGluValIleProLeuThrGluGluAlaGluLeuGluLeuAla     355360365     GluAsnArgGluIleLeuLysGluProValHisGlyValTyrTyrAsp     370375380     ProSerLysAspLeuIleAlaGluValGlnLysGlnGlyGlnGlyGln     385390395400     TrpThrTyrGlnIleTyrGlnGluProPheLysAsnLeuLysThrGly     405410415     LysTyrAlaArgMetArgGlyAlaHisThrAsnAspValLysGlnLeu     420425430     ThrGluAlaValGlnLysIleAlaThrGluSerIleValIleTrpGly     435440445     LysThrProLysPheArgLeuProIleGlnLysGluThrTrpGluThr     450455460     TrpTrpThrGluTyrThrXaaAlaThrTrpIleProGluTrpGluVal     465470475480     ValAsnThrProProLeuValLysLeuTrpTyrGlnLeuGluLysGlu     485490495     ProIleValGlyAlaGluThrPheTyrValAspGlyAlaAlaSerArg     500505510     GluThrLysLysGlyLysAlaGlyTyrLeuThrAsnLysGlyArgGln     515520525     LysValValSerLeuThrAspThrThrAsnGlnLysThrGluLeuGln     530535540     AlaIleHisLeuAlaLeuGlnAspSerGlyLeuGluValAsnIleVal     545550555560     ThrAspSerGlnTyrAlaLeuGlyIleIleGlnAlaGlnProAspLys     565570575     SerGluSerGluLeuValSerGlnIleIleGluGlnLeuIleLysLys     580585590     GluLysValTyrLeuAlaTrpValProAlaHisLysGlyIleGlyGly     595600605     AsnGluGlnValAspLysLeuValSerAlaGlyIleArgLysIleLeu     610615620     PheLeuAspGlyIleAspLysAlaGlnGluAspHisGluLysTyrHis     625630635640     SerAsnTrpArgAlaMetAlaSerAspPheAsnLeuProProIleVal     645650655     AlaLysGluIleValAlaSerCysAspLysCysGlnLeuLysGlyGlu     660665670     AlaMetHisGlyGlnValAspCysSerProGlyIleTrpGlnLeuAsp     675680685     CysThrHisLeuGluGlyLysValIleLeuValAlaValHisValAla     690695700     SerGlyTyrIleGluAlaGluValIleProAlaGluThrGlyGlnGlu     705710715720     ThrAlaTyrPheLeuLeuLysLeuAlaGlyArgTrpProValLysThr     725730735     IleHisThrAspAsnGlyProAsnPheThrSerThrThrValLysAla     740745750     AlaCysTrpTrpThrGlyIleLysGlnGluPheGlyIleProTyrAsn     755760765     ProGlnSerGlnGlyValIleGluSerMetAsnLysGluLeuLysLys     770775780     IleIleGlyGlnValArgAspGlnAlaGluHisLeuLysArgAlaVal     785790795800     GlnMetAlaValPheIleHisAsnPheLysArgLysGlyGlyIleGly     805810815     GlyTyrSerAlaGlyGluArgIleValGlyIleIleAlaThrAspIle     820825830     GlnThrLysGluLeuGlnLysGlnIleThrLysIleGlnAsnPheArg     835840845     ValTyrTyrArgAspSerArgAspProLeuTrpLysGlyProAlaLys     850855860     LeuLeuTrpLysGlyGluGlyAlaValValIleGlnAspAsnAsnAsp     865870875880     IleLysValValProArgArgLysAlaLysValIleArgAspTyrGly     885890895     LysGlnThrAlaGlyAspAspCysValAlaSerArgGlnAspGluAsp     900905910     Xaa     (2) INFORMATION FOR SEQ ID NO:7:     (i) SEQUENCE CHARACTERISTICS:     (A) LENGTH: 1004 amino acids     (B) TYPE: amino acid     (C) STRANDEDNESS: Not Relevant     (D) TOPOLOGY: Not Relevant     (ii) MOLECULE TYPE: protein     (iii) HYPOTHETICAL: NO     (v) FRAGMENT TYPE: internal     (vi) ORIGINAL SOURCE:     (A) ORGANISM: Human immunodeficiency virus type 1     (B) STRAIN: SF2     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:     PhePheArgGluAspLeuAlaPheLeuGlnGlyLysAlaArgGluPhe     151015     SerSerGluGlnThrArgAlaAsnSerProThrArgArgGluLeuGln     202530     ValTrpGlyGlyGluAsnAsnSerLeuSerGluAlaGlyAlaAspArg     354045     GlnGlyThrValSerPheAsnPheProGlnIleThrLeuTrpGlnArg     505560     ProLeuValThrIleArgIleGlyGlyGlnLeuLysGluAlaLeuLeu     65707580     AspThrGlyAlaAspAspThrValLeuGluGluMetAsnLeuProGly     859095     LysTrpLysProLysMetIleGlyGlyIleGlyGlyPheIleLysVal     100105110     ArgGlnTyrAspGlnIleProValGluIleCysGlyHisLysAlaIle     115120125     GlyThrValLeuValGlyProThrProValAsnIleIleGlyArgAsn     130135140     LeuLeuThrGlnIleGlyCysThrLeuAsnPheProIleSerProIle     145150155160     GluThrValProValLysLeuLysProGlyMetAspGlyProLysVal     165170175     LysGlnTrpProLeuThrGluGluLysIleLysAlaLeuValGluIle     180185190     CysThrGluMetGluLysGluGlyLysIleSerLysIleGlyProGlu     195200205     AsnProTyrAsnThrProValPheAlaIleLysLysLysAspSerThr     210215220     LysTrpArgLysLeuValAspPheArgGluLeuAsnLysArgThrGln     225230235240     AspPheTrpGluValGlnLeuGlyIleProHisProAlaGlyLeuLys     245250255     LysLysLysSerValThrValLeuAspValGlyAspAlaTyrPheSer     260265270     ValProLeuAspLysAspPheArgLysTyrThrAlaPheThrIlePro     275280285     SerIleAsnAsnGluThrProGlyIleArgTyrGlnTyrAsnValLeu     290295300     ProGlnGlyTrpLysGlySerProAlaIlePheGlnSerSerMetThr     305310315320     LysIleLeuGluProPheArgLysGlnAsnProAspIleValIleTyr     325330335     GlnTyrMetAspAspLeuTyrValGlySerAspLeuGluIleGlyGln     340345350     HisArgThrLysIleGluGluLeuArgGlnHisLeuLeuArgTrpGly     355360365     PheThrThrProAspLysLysHisGlnLysGluProProPheLeuTrp     370375380     MetGlyTyrGluLeuHisProAspLysTrpThrValGlnProIleMet     385390395400     LeuProGluLysAspSerTrpThrValAsnAspIleGlnLysLeuVal     405410415     GlyLysLeuAsnTrpAlaSerGlnIleTyrAlaGlyIleLysValLys     420425430     GlnLeuCysLysLeuLeuArgGlyThrLysAlaLeuThrGluValIle     435440445     ProLeuThrGluGluAlaGluLeuGluLeuAlaGluAsnArgGluIle     450455460     LeuLysGluProValHisGluValTyrTyrAspProSerLysAspLeu     465470475480     ValAlaGluIleGlnLysGlnGlyGlnGlyGlnTrpThrTyrGlnIle     485490495     TyrGlnGluProPheLysAsnLeuLysThrGlyLysTyrAlaArgMet     500505510     ArgGlyAlaHisThrAsnAspValLysGlnLeuThrGluAlaValGln     515520525     LysValSerThrGluSerIleValIleTrpGlyLysIleProLysPhe     530535540     LysLeuProIleGlnLysGluThrTrpGluAlaTrpTrpMetGluTyr     545550555560     TrpGlnAlaThrTrpIleProGluTrpGluPheValAsnThrProPro     565570575     LeuValLysLeuTrpTyrGlnLeuGluLysGluProIleValGlyAla     580585590     GluThrPheTyrValAspGlyAlaAlaAsnArgGluThrLysLeuGly     595600605     LysAlaGlyTyrValThrAspArgGlyArgGlnLysValValSerIle     610615620     AlaAspThrThrAsnGlnLysThrGluLeuGlnAlaIleHisLeuAla     625630635640     LeuGlnAspSerGlyLeuGluValAsnIleValThrAspSerGlnTyr     645650655     AlaLeuGlyIleIleGlnAlaGlnProAspLysSerGluSerGluLeu     660665670     ValSerGlnIleIleGluGlnLeuIleLysLysGluLysValTyrLeu     675680685     AlaTrpValProAlaHisLysGlyIleGlyGlyAsnGluGlnValAsp     690695700     LysLeuValSerAlaGlyIleArgLysValLeuPheLeuAsnGlyIle     705710715720     AspLysAlaGlnGluGluHisGluLysTyrHisSerAsnTrpArgAla     725730735     MetAlaSerAspPheAsnLeuProProValValAlaLysGluIleVal     740745750     AlaSerCysAspLysCysGlnLeuLysGlyGluAlaMetHisGlyGln     755760765     ValAspCysSerProGlyIleTrpGlnLeuAspCysThrHisLeuGlu     770775780     GlyLysIleIleLeuValAlaValHisValAlaSerGlyTyrIleGlu     785790795800     AlaGluValIleProAlaGluThrGlyGlnGluThrAlaTyrPheLeu     805810815     LeuLysLeuAlaGlyArgTrpProValLysThrIleHisThrAspAsn     820825830     GlySerAsnPheThrSerThrThrValLysAlaAlaCysTrpTrpAla     835840845     GlyIleLysGlnGluPheGlyIleProTyrAsnProGlnSerGlnGly     850855860     ValValGluSerMetAsnAsnGluLeuLysLysIleIleGlyGlnVal     865870875880     ArgAspGlnAlaGluHisLeuLysThrAlaValGlnMetAlaValPhe     885890895     IleHisAsnPheLysArgLysGlyGlyIleGlyGlyTyrSerAlaGly     900905910     GluArgIleValAspIleIleAlaThrAspIleGlnThrLysGluLeu     915920925     GlnLysGlnIleThrLysIleGlnAsnPheArgValTyrTyrArgAsp     930935940     AsnLysAspProLeuTrpLysGlyProAlaLysLeuLeuTrpLysGly     945950955960     GluGlyAlaValValIleGlnAspAsnSerAspIleLysValValPro     965970975     ArgArgLysAlaLysIleIleArgAspTyrGlyLysGlnMetAlaGly     980985990     AspAspCysValAlaSerArgGlnAspGluAspXaa     9951000     (2) INFORMATION FOR SEQ ID NO:8:     (i) SEQUENCE CHARACTERISTICS:     (A) LENGTH: 1003 amino acids     (B) TYPE: amino acid     (C) STRANDEDNESS: Not Relevant     (D) TOPOLOGY: Not Relevant     (ii) MOLECULE TYPE: protein     (iii) HYPOTHETICAL: NO     (v) FRAGMENT TYPE: internal     (vi) ORIGINAL SOURCE:     (A) ORGANISM: Human immunodeficiency virus type 1     (B) STRAIN: RF     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:     PhePheArgGluAsnLeuAlaPheProGlnGlyLysAlaArgGluLeu     151015     SerSerGluGlnThrArgAlaAsnSerProThrArgArgGluLeuGln     202530     ValTrpGlyArgAspAsnSerLeuSerGluAlaGlyGluAspArgGln     354045     GlyThrValSerPheSerPheProGlnIleThrLeuTrpGlnArgPro     505560     IleValThrValLysIleGlyGlyGlnLeuLysGluAlaLeuLeuAsp     65707580     ThrGlyAlaAspAspThrValLeuGluGluMetAsnLeuProGlyLys     859095     TrpLysProLysMetIleGlyGlyIleGlyGlyPheIleLysValArg     100105110     GlnTyrAspGlnIleLeuIleGluIleCysGlyHisLysAlaIleGly     115120125     ThrValLeuValGlyProThrProValAsnIleIleGlyArgAsnLeu     130135140     LeuThrGlnIleGlyCysThrLeuAsnPheProIleSerProIleGlu     145150155160     ThrValProValLysLeuLysProGlyMetAspGlyProLysValLys     165170175     GlnTrpProLeuThrGluGluLysIleLysAlaLeuValGluIleCys     180185190     ThrGluMetGluLysGluGlyLysIleSerLysIleGlyProGluAsn     195200205     ProTyrAsnThrProValPheAlaIleLysLysLysAspSerThrLys     210215220     TrpArgLysLeuValAspPheArgGluLeuAsnLysArgThrGlnAsp     225230235240     PheTrpGluValGlnLeuGlyIleProHisProAlaGlyLeuLysLys     245250255     LysLysSerValThrValLeuAspValGlyAspAlaTyrPheSerVal     260265270     ProLeuAspLysGluPheArgLysTyrThrAlaPheThrIleProSer     275280285     IleAsnAsnGluThrProArgIleArgTyrGlnTyrAsnValLeuPro     290295300     GlnGlyTrpLysGlySerProAlaIlePheGlnSerSerMetThrLys     305310315320     IleLeuGluProPheLysLysGlnAsnProGluIleValIleTyrGln     325330335     TyrMetAspAspLeuTyrValGlySerAspLeuGluIleGlyGlnHis     340345350     ArgIleLysIleGluGluLeuArgGluHisLeuLeuLysTrpGlyPhe     355360365     ThrThrProAspLysLysHisGlnLysGluProProPheLeuTrpMet     370375380     GlyTyrGluLeuHisProAspLysTrpThrValGlnProIleValLeu     385390395400     ProGluLysAspSerTrpThrValAsnAspIleGlnLysLeuValGly     405410415     LysLeuAsnTrpAlaSerGlnIleTyrAlaGlyIleLysValLysGln     420425430     LeuCysLysLeuLeuArgGlyThrLysAlaLeuThrGluValValGln     435440445     LeuThrLysGluAlaGluLeuGluLeuAlaGluAsnArgGluIleLeu     450455460     LysGluProValHisGlyValTyrTyrAspProSerLysAspLeuIle     465470475480     AlaGluIleGlnLysGlnGlyGlnGlyGlnTrpThrTyrGlnIleTyr     485490495     GlnGluProPheLysAsnLeuLysThrGlyLysTyrAlaArgMetArg     500505510     GlyAlaHisThrAsnAspValLysGlnLeuThrGluAlaValGlnLys     515520525     ValAlaThrGluSerIleValIleTrpGlyLysThrProLysPheLys     530535540     LeuProIleGlnLysGluThrTrpGluAlaTrpTrpThrGluTyrTrp     545550555560     GlnAlaThrTrpIleProGluTrpGluPheValAsnThrProProLeu     565570575     ValLysLeuTrpTyrGlnLeuGluLysGluProIleIleGlyAlaGlu     580585590     ThrPheTyrValAspGlyAlaAlaAsnArgGluThrLysLeuGlyLys     595600605     AlaGlyTyrValThrAspArgGlyArgGlnLysValValSerLeuThr     610615620     AspThrThrAsnGlnLysThrGluLeuGlnAlaIleHisLeuAlaLeu     625630635640     GlnAspSerGlyLeuGluValAsnIleValThrAspSerGlnTyrAla     645650655     LeuGlyIleIleGlnAlaGlnProAspLysSerGluSerGluLeuVal     660665670     SerGlnIleIleGluGlnLeuIleLysLysGluLysValTyrLeuAla     675680685     TrpValProAlaHisLysGlyIleGlyGlyAsnGluGlnValAspArg     690695700     LeuValSerThrGlyIleArgLysValLeuPheLeuAspGlyIleAsp     705710715720     LysAlaGlnAspGluHisGluLysTyrHisSerAsnTrpArgAlaMet     725730735     AlaSerAspPheAsnLeuProProValValAlaLysGluIleValAla     740745750     SerCysAspLysCysGlnLeuLysGlyGluAlaMetHisGlyGlnVal     755760765     AspCysSerProGlyIleTrpGlnLeuAspCysThrHisLeuGluGly     770775780     LysIleIleLeuValAlaValHisValAlaSerGlyTyrIleGluAla     785790795800     GluValIleProAlaGluThrGlyGlnGluThrAlaTyrPheIleLeu     805810815     LysLeuAlaGlyArgTrpProValLysValIleHisThrAspAsnGly     820825830     SerAsnPheThrSerThrThrValLysAlaAlaCysTrpTrpAlaGly     835840845     IleLysGlnGluPheGlyIleProTyrAsnProGlnSerGlnGlyVal     850855860     ValGluSerMetAsnLysGlnLeuLysGlnIleIleGlyGlnValArg     865870875880     AspGlnAlaGluHisLeuLysThrAlaValGlnMetAlaValPheIle     885890895     HisAsnPheLysArgLysGlyGlyIleGlyGlyTyrSerAlaGlyGlu     900905910     ArgIleValAspIleIleAlaThrAspIleGlnThrLysGluLeuGln     915920925     LysGlnIleThrLysIleGlnAsnPheArgValTyrTyrArgAspSer     930935940     ArgAspProLeuTrpLysGlyHisAlaLysLeuLeuTrpLysGlyGlu     945950955960     GlyAlaValValIleGlnAspAsnSerAspIleLysValValProArg     965970975     ArgLysAlaLysIleIleArgAspTyrGlyLysGlnMetAlaGlyAsp     980985990     AspCysValAlaSerArgGlnAspGluAspXaa     9951000     (2) INFORMATION FOR SEQ ID NO:9:     (i) SEQUENCE CHARACTERISTICS:     (A) LENGTH: 1003 amino acids     (B) TYPE: amino acid     (C) STRANDEDNESS: Not Relevant     (D) TOPOLOGY: Not Relevant     (ii) MOLECULE TYPE: protein     (iii) HYPOTHETICAL: NO     (v) FRAGMENT TYPE: internal     (vi) ORIGINAL SOURCE:     (A) ORGANISM: Human immunodeficiency virus type 1     (B) STRAIN: MAL     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:     PhePheArgGluAsnLeuAlaPheProGlnGlyLysAlaArgGluPhe     151015     ProSerGluGlnThrArgAlaAsnSerProThrSerArgGluLeuArg     202530     ValTrpGlyGlyAspLysThrLeuSerGluThrGlyAlaGluArgGln     354045     GlyIleValSerPheSerPheProGlnIleThrLeuTrpGlnArgPro     505560     ValValThrValArgValGlyGlyGlnLeuLysGluAlaLeuLeuAsp     65707580     ThrGlyAlaAspAspThrValLeuGluGluIleAsnLeuProGlyLys     859095     TrpLysProLysMetIleGlyGlyIleGlyGlyPheIleLysValArg     100105110     GlnTyrAspGlnIleLeuIleGluIleCysGlyLysLysAlaIleGly     115120125     ThrIleLeuValGlyProThrProValAsnIleIleGlyArgAsnMet     130135140     LeuThrGlnIleGlyCysThrLeuAsnPheProIleSerProIleGlu     145150155160     ThrValProValLysLeuLysProGlyMetAspGlyProArgValLys     165170175     GlnTrpProLeuThrGluGluLysIleLysAlaLeuThrGluIleCys     180185190     LysAspMetGluLysGluGlyLysIleLeuLysIleGlyProGluAsn     195200205     ProTyrAsnThrProValPheAlaIleLysLysLysAspSerThrLys     210215220     TrpArgLysLeuValAsnPheArgGluLeuAsnLysArgThrGlnAsp     225230235240     PheTrpGluValGlnLeuGlyIleProHisProAlaGlyLeuLysLys     245250255     LysLysSerValThrValLeuAspValGlyAspAlaTyrPheSerVal     260265270     ProLeuAspGluAspPheArgLysTyrThrAlaPheThrIleProSer     275280285     IleAsnAsnGluThrProGlyIleArgTyrGlnTyrAsnValLeuPro     290295300     GlnGlyTrpLysGlySerProAlaIlePheGlnSerSerMetThrLys     305310315320     IleLeuGluProPheArgThrLysAsnProGluIleValIleTyrGln     325330335     TyrMetAspAspLeuTyrValGlySerAspLeuGluIleGlyGlnHis     340345350     ArgThrLysIleGluGluLeuArgGluHisLeuLeuLysTrpGlyPhe     355360365     ThrThrProAspLysLysHisGlnLysGluProProPheLeuTrpMet     370375380     GlyTyrGluLeuHisProAspLysTrpThrValGlnProIleGlnLeu     385390395400     ProAspLysGluSerTrpThrValAsnAspIleGlnLysLeuValGly     405410415     LysLeuAsnTrpAlaSerGlnIleTyrProGlyIleLysValLysGln     420425430     LeuCysLysLeuLeuArgGlyAlaLysAlaLeuThrAspIleValPro     435440445     LeuThrAlaGluAlaGluLeuGluLeuAlaGluAsnArgGluIleLeu     450455460     LysGluProValHisGlyValTyrTyrAspProSerLysAspLeuIle     465470475480     AlaGluIleGlnLysGlnGlyGlnGlyGlnTrpThrTyrGlnIleTyr     485490495     GlnGluGlnTyrLysAsnLeuLysThrGlyLysTyrAlaArgIleLys     500505510     SerAlaHisThrAsnAspValLysGlnLeuThrGluAlaValGlnLys     515520525     IleAlaGlnGluSerIleValIleTrpGlyLysThrProLysPheArg     530535540     LeuProIleGlnLysGluThrTrpGluAlaTrpTrpThrGluTyrTrp     545550555560     GlnAlaThrTrpIleProGluTrpGluPheValAsnThrProProLeu     565570575     ValLysLeuTrpTyrGlnLeuGluThrGluProIleValGlyAlaGlu     580585590     ThrPheTyrValAspGlyAlaAlaAsnArgGluThrLysLysGlyLys     595600605     AlaGlyTyrValThrAspArgGlyArgGlnLysValValSerLeuThr     610615620     GluThrThrAsnGlnLysThrGluLeuGlnAlaIleHisLeuAlaLeu     625630635640     GlnAspSerGlyLeuGluValAsnIleValThrAspSerGlnTyrAla     645650655     LeuGlyIleIleGlnAlaGlnProAspLysSerGluSerGluIleVal     660665670     AsnGlnIleIleGluGlnLeuIleGlnLysAspLysValTyrLeuSer     675680685     TrpValProAlaHisLysGlyIleGlyGlyAsnGluGlnValAspLys     690695700     LeuValSerSerGlyIleArgLysValLeuPheLeuAspGlyIleAsp     705710715720     LysAlaGlnGluGluHisGluLysTyrHisSerAsnTrpArgAlaMet     725730735     AlaSerAspPheAsnLeuProProIleValAlaLysGluIleValAla     740745750     SerCysAspLysCysGlnLeuLysGlyGluAlaMetHisGlyGlnVal     755760765     AspCysSerProGlyIleTrpGlnLeuAspCysThrHisLeuGluGly     770775780     LysIleIleIleValAlaValHisValAlaSerGlyTyrIleGluAla     785790795800     GluValIleProAlaGluThrGlyGlnGluThrAlaTyrPheIleLeu     805810815     LysLeuAlaGlyArgTrpProValLysValValHisThrAspAsnGly     820825830     SerAsnPheThrSerAlaAlaValLysAlaAlaCysTrpTrpAlaAsn     835840845     IleLysGlnGluPheGlyIleProTyrAsnProGlnSerGlnGlyVal     850855860     ValGluSerMetAsnLysGluLeuLysLysIleIleGlyGlnValArg     865870875880     GluGlnAlaGluHisLeuLysThrAlaValGlnMetAlaValPheIle     885890895     HisAsnPheLysArgLysGlyGlyIleGlyGlyTyrSerAlaGlyGlu     900905910     ArgIleIleAspMetIleAlaThrAspIleGlnThrLysGluLeuGln     915920925     LysGlnIleThrLysIleGlnAsnPheArgValTyrTyrArgAspAsn     930935940     ArgAspProIleTrpLysGlyProAlaLysLeuLeuTrpLysGlyGlu     945950955960     GlyAlaValValIleGlnAspAsnSerAspIleLysValValProArg     965970975     ArgLysAlaLysIleIleArgAspTyrGlyLysGlnMetAlaGlyAsp     980985990     AspCysValAlaGlyGlyGlnAspGluAspXaa     9951000     (2) INFORMATION FOR SEQ ID NO:10:     (i) SEQUENCE CHARACTERISTICS:     (A) LENGTH: 1003 amino acids     (B) TYPE: amino acid     (C) STRANDEDNESS: Not Relevant     (D) TOPOLOGY: Not Relevant     (ii) MOLECULE TYPE: protein     (iii) HYPOTHETICAL: NO     (v) FRAGMENT TYPE: internal     (vi) ORIGINAL SOURCE:     (A) ORGANISM: Human immunodeficiency virus type 1     (B) STRAIN: ELI     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:     PhePheArgGluAsnLeuAlaPheProGlnGlyLysAlaGlyGluLeu     151015     SerProLysGlnThrArgAlaAsnSerProThrSerArgGluLeuArg     202530     ValTrpGlyArgAspAsnProLeuSerLysThrGlyAlaGluArgGln     354045     GlyThrValSerPheAsnPheProGlnIleThrLeuTrpGlnArgPro     505560     LeuValAlaIleLysIleGlyGlyGlnLeuLysGluAlaLeuLeuAsp     65707580     ThrGlyAlaAspAspThrValLeuGluGluMetAsnLeuProGlyLys     859095     TrpLysProLysMetIleGlyGlyIleGlyGlyPheIleLysValArg     100105110     GlnTyrAspGlnIleProIleGluIleCysGlyGlnLysAlaIleGly     115120125     ThrValLeuValGlyProThrProValAsnIleIleGlyArgAsnLeu     130135140     LeuThrGlnIleGlyCysThrLeuAsnPheProIleSerProIleGlu     145150155160     ThrValProValLysLeuLysProGlyMetAspGlyProLysValLys     165170175     GlnTrpProLeuThrGluGluLysIleLysAlaLeuThrGluIleCys     180185190     ThrAspMetGluLysGluGlyLysIleSerArgIleGlyProGluAsn     195200205     ProTyrAsnThrProIlePheAlaIleLysLysLysAspSerThrLys     210215220     TrpArgLysLeuValAspPheArgGluLeuAsnLysArgThrGlnAsp     225230235240     PheTrpGluValGlnLeuGlyIleProHisProAlaGlyLeuLysLys     245250255     LysLysSerValThrValLeuAspValGlyAspAlaTyrPheSerVal     260265270     ProLeuAspGluAspPheArgLysTyrThrAlaPheThrIleSerSer     275280285     IleAsnAsnGluThrProGlyIleArgTyrGlnTyrAsnValLeuPro     290295300     GlnGlyTrpLysGlySerProAlaIlePheGlnSerSerMetThrLys     305310315320     IleLeuGluProPheArgLysGlnAsnProGluMetValIleTyrGln     325330335     TyrMetAspAspLeuTyrValGlySerAspLeuGluIleGlyGlnHis     340345350     ArgThrLysIleGluLysLeuArgGluHisLeuLeuArgTrpGlyPhe     355360365     ThrArgProAspLysLysHisGlnLysGluProProPheLeuTrpMet     370375380     GlyTyrGluLeuHisProAspLysTrpThrValGlnSerIleLysLeu     385390395400     ProGluLysGluSerTrpThrValAsnAspIleGlnAsnLeuValGlu     405410415     ArgLeuAsnTrpAlaSerGlnIleTyrProGlyIleLysValArgGln     420425430     LeuCysLysLeuLeuArgGlyThrLysAlaLeuThrGluValIlePro     435440445     LeuThrGluGluAlaGluLeuGluLeuAlaGluAsnArgGluIleLeu     450455460     LysGluProValHisGlyValTyrTyrAspProSerLysAspLeuIle     465470475480     AlaGluIleGlnLysGlnGlyHisGlyGlnTrpThrTyrGlnIleTyr     485490495     GlnGluProPheLysAsnLeuLysThrGlyLysTyrAlaArgMetArg     500505510     GlyAlaHisThrAsnAspValLysGlnLeuAlaGluAlaValGlnArg     515520525     IleSerThrGluSerIleValIleTrpGlyArgThrProLysPheArg     530535540     LeuProIleGlnLysGluThrTrpGluThrTrpTrpAlaGluTyrTrp     545550555560     GlnAlaThrTrpIleProGluTrpGluPheValAsnThrProProLeu     565570575     ValLysLeuTrpTyrGlnLeuGluLysGluProIleIleGlyAlaGlu     580585590     ThrPheTyrValAspGlyAlaAlaAsnArgGluThrLysLeuGlyLys     595600605     AlaGlyTyrValThrAspArgGlyArgGlnLysValValProLeuThr     610615620     AspThrThrAsnGlnLysThrGluLeuGlnAlaIleAsnLeuAlaLeu     625630635640     GlnAspSerGlyLeuGluValAsnIleValThrAspSerGlnTyrAla     645650655     LeuGlyIleIleGlnAlaGlnProAspLysSerGluSerGluLeuVal     660665670     AsnGlnIleIleGluGlnLeuIleLysLysGluLysValTyrLeuAla     675680685     TrpValProAlaHisLysGlyIleGlyGlyAsnGluGlnValAspLys     690695700     LeuValSerGlnGlyIleArgLysValLeuPheLeuAspGlyIleAsp     705710715720     LysAlaGlnGluGluHisGluLysTyrHisAsnAsnTrpArgAlaMet     725730735     AlaSerAspPheAsnLeuProProValValAlaLysGluIleValAla     740745750     SerCysAspLysCysGlnLeuLysGlyGluAlaMetHisGlyGlnVal     755760765     AspCysSerProGlyIleTrpGlnLeuAspCysThrHisLeuGluGly     770775780     LysValIleLeuValAlaValHisValAlaSerGlyTyrIleGluAla     785790795800     GluValIleProAlaGluThrGlyGlnGluThrAlaTyrPheLeuLeu     805810815     LysLeuAlaGlyArgTrpProValLysValValHisThrAspAsnGly     820825830     SerAsnPheThrSerAlaAlaValLysAlaAlaCysTrpTrpAlaGly     835840845     IleLysGlnGluPheGlyIleProTyrAsnProGlnSerGlnGlyVal     850855860     ValGluSerMetAsnLysGluLeuLysLysIleIleGlyGlnValArg     865870875880     AspGlnAlaGluHisLeuLysThrAlaValGlnMetAlaValPheIle     885890895     HisAsnPheLysArgArgArgGlyIleGlyGlyTyrSerAlaGlyGlu     900905910     ArgIleIleAspIleIleAlaThrAspIleGlnThrLysGluLeuGln     915920925     LysGlnIleIleLysIleGlnAsnPheArgValTyrTyrArgAspSer     930935940     ArgAspProIleTrpLysGlyProAlaLysLeuLeuTrpLysGlyGlu     945950955960     GlyAlaValValIleGlnAspLysSerAspIleLysValValProArg     965970975     ArgValAlaLysIleIleArgAspTyrGlyLysGlnMetAlaGlyAsp     980985990     AspCysValAlaSerArgGlnAspGluAspXaa     9951000     (2) INFORMATION FOR SEQ ID NO:11:     (i) SEQUENCE CHARACTERISTICS:     (A) LENGTH: 10 base pairs     (B) TYPE: nucleic acid     (C) STRANDEDNESS: single     (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (iii) HYPOTHETICAL: NO     (iv) ANTI-SENSE: NO     (vi) ORIGINAL SOURCE:     (A) ORGANISM: Spodoptera frugiperda     (B) STRAIN: SF9     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:     ACCTATAAAT10     (2) INFORMATION FOR SEQ ID NO:12:     (i) SEQUENCE CHARACTERISTICS:     (A) LENGTH: 29 base pairs     (B) TYPE: nucleic acid     (C) STRANDEDNESS: single     (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (iii) HYPOTHETICAL: NO     (iv) ANTI-SENSE: NO     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:     CGGATCCTATAAATATGAGTTTGCCAGGA29     (2) INFORMATION FOR SEQ ID NO:13:     (i) SEQUENCE CHARACTERISTICS:     (A) LENGTH: 30 base pairs     (B) TYPE: nucleic acid     (C) STRANDEDNESS: single     (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (iii) HYPOTHETICAL: NO     (iv) ANTI-SENSE: NO     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:     TGGCAAACTCATATTTATAGGATCCGAGCT30     (2) INFORMATION FOR SEQ ID NO:14:     (i) SEQUENCE CHARACTERISTICS:     (A) LENGTH: 25 base pairs     (B) TYPE: nucleic acid     (C) STRANDEDNESS: single     (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (iii) HYPOTHETICAL: NO     (iv) ANTI-SENSE: NO     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:     CAGGATGAGGATTAGGATCCGCATG25     (2) INFORMATION FOR SEQ ID NO:15:     (i) SEQUENCE CHARACTERISTICS:     (A) LENGTH: 18 base pairs     (B) TYPE: nucleic acid     (C) STRANDEDNESS: single     (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (iii) HYPOTHETICAL: NO     (iv) ANTI-SENSE: NO     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:     CGGATCCTAATCCTCATC18     (2) INFORMATION FOR SEQ ID NO:16:     (i) SEQUENCE CHARACTERISTICS:     (A) LENGTH: 2739 base pairs     (B) TYPE: nucleic acid     (C) STRANDEDNESS: single     (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (iii) HYPOTHETICAL: NO     (iv) ANTI-SENSE: NO     (vi) ORIGINAL SOURCE:     (A) ORGANISM: Human immunodeficiency virus type 1     (B) STRAIN: HXB2     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:     ATGAGTTTGCCAGGAAGATGGAAACCAAAAATGATAGGGGGAATTGGAGGTTTTATCAAA60     GTAAGACAGTATGATCAGATACTCATAGAAATCTGTGGACATAAAGCTATAGGTACAGTA120     TTAGTAGGACCTACACCTGTCAACATAATTGGAAGAAATCTGTTGACTCAGATTGGTTGC180     ACTTTAAATTTTCCCATTAGCCCTATTGAGACTGTACCAGTAAAATTAAAGCCAGGAATG240     GATGGCCCAAAAGTTAAACAATGGCCATTGACAGAAGAAAAAATAAAAGCATTAGTAGAA300     ATTTGTACAGAGATGGAAAAGGAAGGGAAAATTTCAAAAATTGGGCCTGAAAATCCATAC360     AATACTCCAGTATTTGCCATAAAGAAAAAAGACAGTACTAAATGGAGAAAATTAGTAGAT420     TTCAGAGAACTTAATAAGAGAACTCAAGACTTCTGGGAAGTTCAATTAGGAATACCACAT480     CCCGCAGGGTTAAAAAAGAAAAAATCAGTAACAGTACTGGATGTGGGTGATGCATATTTT540     TCAGTTCCCTTAGATGAAGACTTCAGGAAGTATACTGCATTTACCATACCTAGTATAAAC600     AATGAGACACCAGGGATTAGATATCAGTACAATGTGCTTCCACAGGGATGGAAAGGATCA660     CCAGCAATATTCCAAAGTAGCATGACAAAAATCTTAGAGCCTTTTAGAAAACAAAATCCA720     GACATAGTTATCTATCAATACATGGATGATTTGTATGTAGGATCTGACTTAGAAATAGGG780     CAGCATAGAACAAAAATAGAGGAGCTGAGACAACATCTGTTGAGGTGGGGACTTACCACA840     CCAGACAAAAAACATCAGAAAGAACCTCCATTCCTTTGGATGGGTTATGAACTCCATCCT900     GATAAATGGACAGTACAGCCTATAGTGCTGCCAGAAAAAGACAGCTGGACTGTCAATGAC960     ATACAGAAGTTAGTGGGGAAATTGAATTGGGCAAGTCAGATTTACCCAGGGATTAAAGTA1020     AGGCAATTATGTAAACTCCTTAGAGGAACCAAAGCACTAACAGAAGTAATACCACTAACA1080     GAAGAAGCAGAGCTAGAACTGGCAGAAAACAGAGAGATTCTAAAAGAACCAGTACATGGA1140     GTGTATTATGACCCATCAAAAGACTTAATAGCAGAAATACAGAAGCAGGGGCAAGGCCAA1200     TGGACATATCAAATTTATCAAGAGCCATTTAAAAATCTGAAAACAGGAAAATATGCAAGA1260     ATGAGGGGTGCCCACACTAATGATGTAAAACAATTAACAGAGGCAGTGCAAAAAATAACC1320     ACAGAAAGCATAGTAATATGGGGAAAGACTCCTAAATTTAAACTGCCCATACAAAAGGAA1380     ACATGGGAAACATGGTGGACAGAGTATTGGCAAGCCACCTGGATTCCTGAGTGGGAGTTT1440     GTTAATACCCCTCCCTTAGTGAAATTATGGTACCAGTTAGAGAAAGAACCCATAGTAGGA1500     GCAGAAACCTTCTATGTAGATGGGGCAGCTAACAGGGAGACTAAATTAGGAAAAGCAGGA1560     TATGTTACTAATAGAGGAAGACAAAAAGTTGTCACCCTAACTGACACAACAAATCAGAAG1620     ACTGAGTTACAAGCAATTTATCTAGCTTTGCAGGATTCGGGATTAGAAGTAAACATAGTA1680     ACAGACTCACAATATGCATTAGGAATCATTCAAGCACAACCAGATCAAAGTGAATCAGAG1740     TTAGTCAATCAAATAATAGAGCAGTTAATAAAAAAGGAAAAGGTCTATCTGGCATGGGTA1800     CCAGCACACAAAGGAATTGGAGGAAATGAACAAGTAGATAAATTAGTCAGTGCTGGAATC1860     AGGAAAGTACTATTTTTAGATGGAATAGATAAGGCCCAAGATGAACATGAGAAATATCAC1920     AGTAATTGGAGAGCAATGGCTAGTGATTTTAACCTGCCACCTGTAGTAGCAAAAGAAATA1980     GTAGCCAGCTGTGATAAATGTCAGCTAAAAGGAGAAGCCATGCATGGACAAGTAGACTGT2040     AGTCCAGGAATATGGCAACTAGATTGTACACATTTAGAAGGAAAAGTTATCCTGGTAGCA2100     GTTCATGTAGCCAGTGGATATATAGAAGCAGAAGTTATTCCAGCAGAAACAGGGCAGGAA2160     ACAGCATATTTTCTTTTAAAATTAGCAGGAAGATGGCCAGTAAAAACAATACATACTGAC2220     AATGGCAGCAATTTCACCGGTGCTACGGTTAGGGCCGCCTGTTGGTGGGCGGGAATCAAG2280     CAGGAATTTGGAATTCCCTACAATCCCCAAAGTCAAGGAGTAGTAGAATCTATGAATAAA2340     GAATTAAAGAAAATTATAGGACAGGTAAGAGATCAGGCTGAACATCTTAAGACAGCAGTA2400     CAAATGGCAGTATTCATCCACAATTTTAAAAGAAAAGGGGGGATTGGGGGGTACAGTGCA2460     GGGGAAAGAATAGTAGACATAATAGCAACAGACATACAAACTAAAGAATTACAAAAACAA2520     ATTACAAAAATTCAAAATTTTCGGGTTTATTACAGGGACAGCAGAAATTCACTTTGGAAA2580     GGACCAGCAAAGCTCCTCTGGAAAGGTGAAGGGGCAGTAGTAATACAAGATAATAGTGAC2640     ATAAAAGTAGTGCCAAGAAGAAAAGCAAAGATCATTAGGGATTATGGAAAACAGATGGCA2700     GGTGATGATTGTGTGGCAAGTAGACAGGATGAGGATTAG2739     (2) INFORMATION FOR SEQ ID NO:17:     (i) SEQUENCE CHARACTERISTICS:     (A) LENGTH: 15 base pairs     (B) TYPE: nucleic acid     (C) STRANDEDNESS: single     (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (iii) HYPOTHETICAL: NO     (iv) ANTI-SENSE: NO     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:     GATCCTATAAATATG15     (2) INFORMATION FOR SEQ ID NO:18:     (i) SEQUENCE CHARACTERISTICS:     (A) LENGTH: 11 base pairs     (B) TYPE: nucleic acid     (C) STRANDEDNESS: single     (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (iii) HYPOTHETICAL: NO     (iv) ANTI-SENSE: NO     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:     CATATTTATAG11     (2) INFORMATION FOR SEQ ID NO:19:     (i) SEQUENCE CHARACTERISTICS:     (A) LENGTH: 3033 base pairs     (B) TYPE: nucleic acid     (C) STRANDEDNESS: single     (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (iii) HYPOTHETICAL: NO     (iv) ANTI-SENSE: NO     (vi) ORIGINAL SOURCE:     (A) ORGANISM: Human immunodeficiency virus type 1     (B) STRAIN: HXB2     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:     GGATCCTATAAATATGTTTTTTAGGGAAGATCTGGCCTTCCTACAAGGGAAGGCCAGGGA60     ATTTTCTTCAGAGCAGACCAGAGCCAACAGCCCCACCAGAAGAGAGCTTCAGGTCTGGGG120     TAGAGACAACAACTCCCCCTCAGAAGCAGGAGCCGATAGACAAGGAACTGTATCCTTTAA180     CTTCCCTCAGGTCACTCTTTGGCAACGACCCCTCGTCACAATAAAGATAGGGGGGCAACT240     AAAGGAAGCTCTATTAGATACAGGAGCAGATGATACAGTATTAGAAGAAATGAGTTTGCC300     AGGAAGATGGAAACCAAAAATGATAGGGGGAATTGGAGGTTTTATCAAAGTAAGACAGTA360     TGATCAGATACTCATAGAAATCTGTGGACATAAAGCTATAGGTACAGTATTAGTAGGACC420     TACACCTGTCAACATAATTGGAAGAAATCTGTTGACTCAGATTGGTTGCACTTTAAATTT480     TCCCATTAGCCCTATTGAGACTGTACCAGTAAAATTAAAGCCAGGAATGGATGGCCCAAA540     AGTTAAACAATGGCCATTGACAGAAGAAAAAATAAAAGCATTAGTAGAAATTTGTACAGA600     GATGGAAAAGGAAGGGAAAATTTCAAAAATTGGGCCTGAAAATCCATACAATACTCCAGT660     ATTTGCCATAAAGAAAAAAGACAGTACTAAATGGAGAAAATTAGTAGATTTCAGAGAACT720     TAATAAGAGAACTCAAGACTTCTGGGAAGTTCAATTAGGAATACCACATCCCGCAGGGTT780     AAAAAAGAAAAAATCAGTAACAGTACTGGATGTGGGTGATGCATATTTTTCAGTTCCCTT840     AGATGAAGACTTCAGGAAGTATACTGCATTTACCATACCTAGTATAAACAATGAGACACC900     AGGGATTAGATATCAGTACAATGTGCTTCCACAGGGATGGAAAGGATCACCAGCAATATT960     CCAAAGTAGCATGACAAAAATCTTAGAGCCTTTTAGAAAACAAAATCCAGACATAGTTAT1020     CTATCAATACATGGATGATTTGTATGTAGGATCTGACTTAGAAATAGGGCAGCATAGAAC1080     AAAAATAGAGGAGCTGAGACAACATCTGTTGAGGTGGGGACTTACCACACCAGACAAAAA1140     ACATCAGAAAGAACCTCCATTCCTTTGGATGGGTTATGAACTCCATCCTGATAAATGGAC1200     AGTACAGCCTATAGTGCTGCCAGAAAAAGACAGCTGGACTGTCAATGACATACAGAAGTT1260     AGTGGGGAAATTGAATTGGGCAAGTCAGATTTACCCAGGGATTAAAGTAAGGCAATTATG1320     TAAACTCCTTAGAGGAACCAAAGCACTAACAGAAGTAATACCACTAACAGAAGAAGCAGA1380     GCTAGAACTGGCAGAAAACAGAGAGATTCTAAAAGAACCAGTACATGGAGTGTATTATGA1440     CCCATCAAAAGACTTAATAGCAGAAATACAGAAGCAGGGGCAAGGCCAATGGACATATCA1500     AATTTATCAAGAGCCATTTAAAAATCTGAAAACAGGAAAATATGCAAGAATGAGGGGTGC1560     CCACACTAATGATGTAAAACAATTAACAGAGGCAGTGCAAAAAATAACCACAGAAAGCAT1620     AGTAATATGGGGAAAGACTCCTAAATTTAAACTGCCCATACAAAAGGAAACATGGGAAAC1680     ATGGTGGACAGAGTATTGGCAAGCCACCTGGATTCCTGAGTGGGAGTTTGTTAATACCCC1740     TCCCTTAGTGAAATTATGGTACCAGTTAGAGAAAGAACCCATAGTAGGAGCAGAAACCTT1800     CTATGTAGATGGGGCAGCTAACAGGGAGACTAAATTAGGAAAAGCAGGATATGTTACTAA1860     TAGAGGAAGACAAAAAGTTGTCACCCTAACTGACACAACAAATCAGAAGACTGAGTTACA1920     AGCAATTTATCTAGCTTTGCAGGATTCGGGATTAGAAGTAAACATAGTAACAGACTCACA1980     ATATGCATTAGGAATCATTCAAGCACAACCAGATCAAAGTGAATCAGAGTTAGTCAATCA2040     AATAATAGAGCAGTTAATAAAAAAGGAAAAGGTCTATCTGGCATGGGTACCAGCACACAA2100     AGGAATTGGAGGAAATGAACAAGTAGATAAATTAGTCAGTGCTGGAATCAGGAAAGTACT2160     ATTTTTAGATGGAATAGATAAGGCCCAAGATGAACATGAGAAATATCACAGTAATTGGAG2220     AGCAATGGCTAGTGATTTTAACCTGCCACCTGTAGTAGCAAAAGAAATAGTAGCCAGCTG2280     TGATAAATGTCAGCTAAAAGGAGAAGCCATGCATGGACAAGTAGACTGTAGTCCAGGAAT2340     ATGGCAACTAGATTGTACACATTTAGAAGGAAAAGTTATCCTGGTAGCAGTTCATGTAGC2400     CAGTGGATATATAGAAGCAGAAGTTATTCCAGCAGAAACAGGGCAGGAAACAGCATATTT2460     TCTTTTAAAATTAGCAGGAAGATGGCCAGTAAAAACAATACATACTGACAATGGCAGCAA2520     TTTCACCGGTGCTACGGTTAGGGCCGCCTGTTGGTGGGCGGGAATCAAGCAGGAATTTGG2580     AATTCCCTACAATCCCCAAAGTCAAGGAGTAGTAGAATCTATGAATAAAGAATTAAAGAA2640     AATTATAGGACAGGTAAGAGATCAGGCTGAACATCTTAAGACAGCAGTACAAATGGCAGT2700     ATTCATCCACAATTTTAAAAGAAAAGGGGGGATTGGGGGGTACAGTGCAGGGGAAAGAAT2760     AGTAGACATAATAGCAACAGACATACAAACTAAAGAATTACAAAAACAAATTACAAAAAT2820     TCAAAATTTTCGGGTTTATTACAGGGACAGCAGAAATTCACTTTGGAAAGGACCAGCAAA2880     GCTCCTCTGGAAAGGTGAAGGGGCAGTAGTAATACAAGATAATAGTGACATAAAAGTAGT2940     GCCAAGAAGAAAAGCAAAGATCATTAGGGATTATGGAAAACAGATGGCAGGTGATGATTG3000     TGTGGCAAGTAGACAGGATGAGGATTAGGATCC3033     (2) INFORMATION FOR SEQ ID NO:20:     (i) SEQUENCE CHARACTERISTICS:     (A) LENGTH: 3856 base pairs     (B) TYPE: nucleic acid     (C) STRANDEDNESS: single     (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (iii) HYPOTHETICAL: NO     (iv) ANTI-SENSE: NO     (vi) ORIGINAL SOURCE:     (A) ORGANISM: Human immunodeficiency virus type 1     (B) STRAIN: HXB2     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:     GGATCCTATAAATATGTACAGTATTAGAAGAAATGAGTTTGCCAGGAAGATGGAAACCAA60     AAATGATAGGGGGAATTGGAGGTTTTATCAAAGTAAGACAGTATGATCAGATACTCATAG120     AAATCTGTGGACATAAAGCTATAGGTACAGTATTAGTAGGACCTACACCTGTCAACATAA180     TTGGAAGAAATCTGTTGACTCAGATTGGTTGCACTTTAAATTTTCCCATTAGCCCTATTG240     AGACTGTACCAGTAAAATTAAAGCCAGGAATGGATGGCCCAAAAGTTAAACAATGGCCAT300     TGACAGAAGAAAAAATAAAAGCATTAGTAGAAATTTGTACAGAGATGGAAAAGGAAGGGA360     AAATTTCAAAAATTGGGCCTGAAAATCCATACAATACTCCAGTATTTGCCATAAAGAAAA420     AAGACAGTACTAAATGGAGAAAATTAGTAGATTTCAGAGAACTTAATAAGAGAACTCAAG480     ACTTCTGGGAAGTTCAATTAGGAATACCACATCCCGCAGGGTTAAAAAAGAAAAAATCAG540     TAACAGTACTGGATGTGGGTGATGCATATTTTTCAGTTCCCTTAGATGAAGACTTCAGGA600     AGTATACTGCATTTACCATACCTAGTATAAACAATGAGACACCAGGGATTAGATATCAGT660     ACAATGTGCTTCCACAGGGATGGAAAGGATCACCAGCAATATTCCAAAGTAGCATGACAA720     AAATCTTAGAGCCTTTTAGAAAACAAAATCCAGACATAGTTATCTATCAATACATGGATG780     ATTTGTATGTAGGATCTGACTTAGAAATAGGGCAGCATAGAACAAAAATAGAGGAGCTGA840     GACAACATCTGTTGAGGTGGGGACTTACCACACCAGACAAAAAACATCAGAAAGAACCTC900     CATTCCTTTGGATGGGTTATGAACTCCATCCTGATAAATGGACAGTACAGCCTATAGTGC960     TGCCAGAAAAAGACAGCTGGACTGTCAATGACATACAGAAGTTAGTGGGGAAATTGAATT1020     GGGCAAGTCAGATTTACCCAGGGATTAAAGTAAGGCAATTATGTAAACTCCTTAGAGGAA1080     CCAAAGCACTAACAGAAGTAATACCACTAACAGAAGAAGCAGAGCTAGAACTGGCAGAAA1140     ACAGAGAGATTCTAAAAGAACCAGTACATGGAGTGTATTATGACCCATCAAAAGACTTAA1200     TAGCAGAAATACAGAAGCAGGGGCAAGGCCAATGGACATATCAAATTTATCAAGAGCCAT1260     TTAAAAATCTGAAAACAGGAAAATATGCAAGAATGAGGGGTGCCCACACTAATGATGTAA1320     AACAATTAACAGAGGCAGTGCAAAAAATAACCACAGAAAGCATAGTAATATGGGGAAAGA1380     CTCCTAAATTTAAACTGCCCATACAAAAGGAAACATGGGAAACATGGTGGACAGAGTATT1440     GGCAAGCCACCTGGATTCCTGAGTGGGAGTTTGTTAATACCCCTCCCTTAGTGAAATTAT1500     GGTACCAGTTAGAGAAAGAACCCATAGTAGGAGCAGAAACCTTCTATGTAGATGGGGCAG1560     CTAACAGGGAGACTAAATTAGGAAAAGCAGGATATGTTACTAATAGAGGAAGACAAAAAG1620     TTGTCACCCTAACTGACACAACAAATCAGAAGACTGAGTTACAAGCAATTTATCTAGCTT1680     TGCAGGATTCGGGATTAGAAGTAAACATAGTAACAGACTCACAATATGCATTAGGAATCA1740     TTCAAGCACAACCAGATCAAAGTGAATCAGAGTTAGTCAATCAAATAATAGAGCAGTTAA1800     TAAAAAAGGAAAAGGTCTATCTGGCATGGGTACCAGCACACAAAGGAATTGGAGGAAATG1860     AACAAGTAGATAAATTAGTCAGTGCTGGAATCAGGAAAGTACTATTTTTAGATGGAATAG1920     ATAAGGCCCAAGATGAACATGAGAAATATCACAGTAATTGGAGAGCAATGGCTAGTGATT1980     TTAACCTGCCACCTGTAGTAGCAAAAGAAATAGTAGCCAGCTGTGATAAATGTCAGCTAA2040     AAGGAGAAGCCATGCATGGACAAGTAGACTGTAGTCCAGGAATATGGCAACTAGATTGTA2100     CACATTTAGAAGGAAAAGTTATCCTGGTAGCAGTTCATGTAGCCAGTGGATATATAGAAG2160     CAGAAGTTATTCCAGCAGAAACAGGGCAGGAAACAGCATATTTTCTTTTAAAATTAGCAG2220     GAAGATGGCCAGTAAAAACAATACATACTGACAATGGCAGCAATTTCACCGGTGCTACGG2280     TTAGGGCCGCCTGTTGGTGGGCGGGAATCAAGCAGGAATTTGGAATTCCCTACAATCCCC2340     AAAGTCAAGGAGTAGTAGAATCTATGAATAAAGAATTAAAGAAAATTATAGGACAGGTAA2400     GAGATCAGGCTGAACATCTTAAGACAGCAGTACAAATGGCAGTATTCATCCACAATTTTA2460     AAAGAAAAGGGGGGATTGGGGGGTACAGTGCAGGGGAAAGAATAGTAGACATAATAGCAA2520     CAGACATACAAACTAAAGAATTACAAAAACAAATTACAAAAATTCAAAATTTTCGGGTTT2580     ATTACAGGGACAGCAGAAATTCACTTTGGAAAGGACCAGCAAAGCTCCTCTGGAAAGGTG2640     AAGGGGCAGTAGTAATACAAGATAATAGTGACATAAAAGTAGTGCCAAGAAGAAAAGCAA2700     AGATCATTAGGGATTATGGAAAACAGATGGCAGGTGATGATTGTGTGGCAAGTAGACAGG2760     ATGAGGATTAGGATCCGGAAAAGTTTAGTAAAACACCATATGTATGTTTCAGGGAAAGCT2820     AGGGGATGGTTTTATAGACATCACTATGAAAGCCCTCATCCAAGAATAAGTTCAGAAGTA2880     CACATCCCACTAGGGGATGCTAGATTGGTAATAACAACATATTGGGGTCTGCATACAGGA2940     GAAAGAGACTGGCATTTGGGTCAGGGAGTCTCCATAGAATGGAGGAAAAAGAGATATAGC3000     ACACAAGTAGACCCTGAACTAGCAGACCAACTAATTCATCTGTATTACTTTGACTGTTTT3060     TCAGACTCTGCTATAAGAAAGGCCTTATTAGGACACATAGTTAGCCCTAGGTGTGAATAT3120     CAAGCAGGACATAACAAGGTAGGATCTCTACAATACTTGGCACTAGCAGCATTAATAACA3180     CCAAAAAAGATAAAGCCACCTTTGCCTAGTGTTACGAAACTGACAGAGGATAGATGGAAC3240     AAGCCCCAGAAGACCAAGGGCCACAGAGGGAGCCACACAATGAATGGACACTAGAGCTTT3300     TAGAGGAGCTTAAGAATGAAGCTGTTAGACATTTTCCTAGGATTTGGCTCCATGGCTTAG3360     GGCAACATATCTATGAAACTTATGGGGATACTTGGGCAGGAGTGGAAGCCATAATAAGAA3420     TTCTGCAACAACTGCTGTTTATCCATTTTCAGAATTGGGTGTCGACATAGCAGAATAGGC3480     GTTACTCGACAGAGGAGAGCAAGAAATGGAGCCAGTAGATCCTAGACTAGAGCCCTGGAA3540     GCATCCAGGAAGTCAGCCTAAAACTGCTTGTACCAATTGCTATTGTAAAAAGTGTTGCTT3600     TCATTGCCAAGTTTGTTTCATAACAAAAGCCTTAGGCATCTCCTATGGCAGGAAGAAGCG3660     GAGACAGCGACGAAGAGCTCATCAGAACAGTCAGACTCATCAAGCTTCTCTATCAAAGCA3720     GTAAGTAGTACATGTAACGCAACCTATACCAATAGTAGCAATAGTAGCATTAGTAGTAGC3780     AATAATAATAGCAATAGTTGTGTGGTCCATAGTAATCATAGAATATAGGAAAATATTAAG3840     ACAAAGAAAAATAGAC3856     (2) INFORMATION FOR SEQ ID NO:21:     (i) SEQUENCE CHARACTERISTICS:     (A) LENGTH: 4113 base pairs     (B) TYPE: nucleic acid     (C) STRANDEDNESS: single     (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: DNA (genomic)     (iii) HYPOTHETICAL: NO     (iv) ANTI-SENSE: NO     (vi) ORIGINAL SOURCE:     (A) ORGANISM: Human immunodeficiency virus type 1     (B) STRAIN: HXB2     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:     GGATCCTATAAATATGTTTTTTAGGGAAGATCTGGCCTTCCTACAAGGGAAGGCCAGGGA60     ATTTTCTTCAGAGCAGACCAGAGCCAACAGCCCCACCAGAAGAGAGCTTCAGGTCTGGGG120     TAGAGACAACAACTCCCCCTCAGAAGCAGGAGCCGATAGACAAGGAACTGTATCCTTTAA180     CTTCCCTCAGGTCACTCTTTGGCAACGACCCCTCGTCACAATAAAGATAGGGGGGCAACT240     AAAGGAAGCTCTATTAGATACAGGAGCAGATGATACAGTATTAGAAGAAATGAGTTTGCC300     AGGAAGATGGAAACCAAAAATGATAGGGGGAATTGGAGGTTTTATCAAAGTAAGACAGTA360     TGATCAGATACTCATAGAAATCTGTGGACATAAAGCTATAGGTACAGTATTAGTAGGACC420     TACACCTGTCAACATAATTGGAAGAAATCTGTTGACTCAGATTGGTTGCACTTTAAATTT480     TCCCATTAGCCCTATTGAGACTGTACCAGTAAAATTAAAGCCAGGAATGGATGGCCCAAA540     AGTTAAACAATGGCCATTGACAGAAGAAAAAATAAAAGCATTAGTAGAAATTTGTACAGA600     GATGGAAAAGGAAGGGAAAATTTCAAAAATTGGGCCTGAAAATCCATACAATACTCCAGT660     ATTTGCCATAAAGAAAAAAGACAGTACTAAATGGAGAAAATTAGTAGATTTCAGAGAACT720     TAATAAGAGAACTCAAGACTTCTGGGAAGTTCAATTAGGAATACCACATCCCGCAGGGTT780     AAAAAAGAAAAAATCAGTAACAGTACTGGATGTGGGTGATGCATATTTTTCAGTTCCCTT840     AGATGAAGACTTCAGGAAGTATACTGCATTTACCATACCTAGTATAAACAATGAGACACC900     AGGGATTAGATATCAGTACAATGTGCTTCCACAGGGATGGAAAGGATCACCAGCAATATT960     CCAAAGTAGCATGACAAAAATCTTAGAGCCTTTTAGAAAACAAAATCCAGACATAGTTAT1020     CTATCAATACATGGATGATTTGTATGTAGGATCTGACTTAGAAATAGGGCAGCATAGAAC1080     AAAAATAGAGGAGCTGAGACAACATCTGTTGAGGTGGGGACTTACCACACCAGACAAAAA1140     ACATCAGAAAGAACCTCCATTCCTTTGGATGGGTTATGAACTCCATCCTGATAAATGGAC1200     AGTACAGCCTATAGTGCTGCCAGAAAAAGACAGCTGGACTGTCAATGACATACAGAAGTT1260     AGTGGGGAAATTGAATTGGGCAAGTCAGATTTACCCAGGGATTAAAGTAAGGCAATTATG1320     TAAACTCCTTAGAGGAACCAAAGCACTAACAGAAGTAATACCACTAACAGAAGAAGCAGA1380     GCTAGAACTGGCAGAAAACAGAGAGATTCTAAAAGAACCAGTACATGGAGTGTATTATGA1440     CCCATCAAAAGACTTAATAGCAGAAATACAGAAGCAGGGGCAAGGCCAATGGACATATCA1500     AATTTATCAAGAGCCATTTAAAAATCTGAAAACAGGAAAATATGCAAGAATGAGGGGTGC1560     CCACACTAATGATGTAAAACAATTAACAGAGGCAGTGCAAAAAATAACCACAGAAAGCAT1620     AGTAATATGGGGAAAGACTCCTAAATTTAAACTGCCCATACAAAAGGAAACATGGGAAAC1680     ATGGTGGACAGAGTATTGGCAAGCCACCTGGATTCCTGAGTGGGAGTTTGTTAATACCCC1740     TCCCTTAGTGAAATTATGGTACCAGTTAGAGAAAGAACCCATAGTAGGAGCAGAAACCTT1800     CTATGTAGATGGGGCAGCTAACAGGGAGACTAAATTAGGAAAAGCAGGATATGTTACTAA1860     TAGAGGAAGACAAAAAGTTGTCACCCTAACTGACACAACAAATCAGAAGACTGAGTTACA1920     AGCAATTTATCTAGCTTTGCAGGATTCGGGATTAGAAGTAAACATAGTAACAGACTCACA1980     ATATGCATTAGGAATCATTCAAGCACAACCAGATCAAAGTGAATCAGAGTTAGTCAATCA2040     AATAATAGAGCAGTTAATAAAAAAGGAAAAGGTCTATCTGGCATGGGTACCAGCACACAA2100     AGGAATTGGAGGAAATGAACAAGTAGATAAATTAGTCAGTGCTGGAATCAGGAAAGTACT2160     ATTTTTAGATGGAATAGATAAGGCCCAAGATGAACATGAGAAATATCACAGTAATTGGAG2220     AGCAATGGCTAGTGATTTTAACCTGCCACCTGTAGTAGCAAAAGAAATAGTAGCCAGCTG2280     TGATAAATGTCAGCTAAAAGGAGAAGCCATGCATGGACAAGTAGACTGTAGTCCAGGAAT2340     ATGGCAACTAGATTGTACACATTTAGAAGGAAAAGTTATCCTGGTAGCAGTTCATGTAGC2400     CAGTGGATATATAGAAGCAGAAGTTATTCCAGCAGAAACAGGGCAGGAAACAGCATATTT2460     TCTTTTAAAATTAGCAGGAAGATGGCCAGTAAAAACAATACATACTGACAATGGCAGCAA2520     TTTCACCGGTGCTACGGTTAGGGCCGCCTGTTGGTGGGCGGGAATCAAGCAGGAATTTGG2580     AATTCCCTACAATCCCCAAAGTCAAGGAGTAGTAGAATCTATGAATAAAGAATTAAAGAA2640     AATTATAGGACAGGTAAGAGATCAGGCTGAACATCTTAAGACAGCAGTACAAATGGCAGT2700     ATTCATCCACAATTTTAAAAGAAAAGGGGGGATTGGGGGGTACAGTGCAGGGGAAAGAAT2760     AGTAGACATAATAGCAACAGACATACAAACTAAAGAATTACAAAAACAAATTACAAAAAT2820     TCAAAATTTTCGGGTTTATTACAGGGACAGCAGAAATTCACTTTGGAAAGGACCAGCAAA2880     GCTCCTCTGGAAAGGTGAAGGGGCAGTAGTAATACAAGATAATAGTGACATAAAAGTAGT2940     GCCAAGAAGAAAAGCAAAGATCATTAGGGATTATGGAAAACAGATGGCAGGTGATGATTG3000     TGTGGCAAGTAGACAGGATGAGGATTAGGATCCGGAAAAGTTTAGTAAAACACCATATGT3060     ATGTTTCAGGGAAAGCTAGGGGATGGTTTTATAGACATCACTATGAAAGCCCTCATCCAA3120     GAATAAGTTCAGAAGTACACATCCCACTAGGGGATGCTAGATTGGTAATAACAACATATT3180     GGGGTCTGCATACAGGAGAAAGAGACTGGCATTTGGGTCAGGGAGTCTCCATAGAATGGA3240     GGAAAAAGAGATATAGCACACAAGTAGACCCTGAACTAGCAGACCAACTAATTCATCTGT3300     ATTACTTTGACTGTTTTTCAGACTCTGCTATAAGAAAGGCCTTATTAGGACACATAGTTA3360     GCCCTAGGTGTGAATATCAAGCAGGACATAACAAGGTAGGATCTCTACAATACTTGGCAC3420     TAGCAGCATTAATAACACCAAAAAAGATAAAGCCACCTTTGCCTAGTGTTACGAAACTGA3480     CAGAGGATAGATGGAACAAGCCCCAGAAGACCAAGGGCCACAGAGGGAGCCACACAATGA3540     ATGGACACTAGAGCTTTTAGAGGAGCTTAAGAATGAAGCTGTTAGACATTTTCCTAGGAT3600     TTGGCTCCATGGCTTAGGGCAACATATCTATGAAACTTATGGGGATACTTGGGCAGGAGT3660     GGAAGCCATAATAAGAATTCTGCAACAACTGCTGTTTATCCATTTTCAGAATTGGGTGTC3720     GACATAGCAGAATAGGCGTTACTCGACAGAGGAGAGCAAGAAATGGAGCCAGTAGATCCT3780     AGACTAGAGCCCTGGAAGCATCCAGGAAGTCAGCCTAAAACTGCTTGTACCAATTGCTAT3840     TGTAAAAAGTGTTGCTTTCATTGCCAAGTTTGTTTCATAACAAAAGCCTTAGGCATCTCC3900     TATGGCAGGAAGAAGCGGAGACAGCGACGAAGAGCTCATCAGAACAGTCAGACTCATCAA3960     GCTTCTCTATCAAAGCAGTAAGTAGTACATGTAACGCAACCTATACCAATAGTAGCAATA4020     GTAGCATTAGTAGTAGCAATAATAATAGCAATAGTTGTGTGGTCCATAGTAATCATAGAA4080     TATAGGAAAATATTAAGACAAAGAAAAATAGAC4113     (2) INFORMATION FOR SEQ ID NO:22:     (i) SEQUENCE CHARACTERISTICS:     (A) LENGTH: 913 amino acids     (B) TYPE: amino acid     (C) STRANDEDNESS:     (D) TOPOLOGY: linear     (ii) MOLECULE TYPE: protein     (iii) HYPOTHETICAL: NO     (v) FRAGMENT TYPE: internal     (vi) ORIGINAL SOURCE:     (A) ORGANISM: Human immunodeficiency virus type 1     (B) STRAIN: HXB2     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:     MetSerLeuProGlyArgTrpLysProLysMetIleGlyGlyIleGly     151015     GlyPheIleLysValArgGlnTyrAspGlnIleLeuIleGluIleCys     202530     GlyHisLysAlaIleGlyThrValLeuValGlyProThrProValAsn     354045     IleIleGlyArgAsnLeuLeuThrGlnIleGlyCysThrLeuAsnPhe     505560     ProIleSerProIleGluThrValProValLysLeuLysProGlyMet     65707580     AspGlyProLysValLysGlnTrpProLeuThrGluGluLysIleLys     859095     AlaLeuValGluIleCysThrGluMetGluLysGluGlyLysIleSer     100105110     LysIleGlyProGluAsnProTyrAsnThrProValPheAlaIleLys     115120125     LysLysAspSerThrLysTrpArgLysLeuValAspPheArgGluLeu     130135140     AsnLysArgThrGlnAspPheTrpGluValGlnLeuGlyIleProHis     145150155160     ProAlaGlyLeuLysLysLysLysSerValThrValLeuAspValGly     165170175     AspAlaTyrPheSerValProLeuAspGluAspPheArgLysTyrThr     180185190     AlaPheThrIleProSerIleAsnAsnGluThrProGlyIleArgTyr     195200205     GlnTyrAsnValLeuProGlnGlyTrpLysGlySerProAlaIlePhe     210215220     GlnSerSerMetThrLysIleLeuGluProPheArgLysGlnAsnPro     225230235240     AspIleValIleTyrGlnTyrMetAspAspLeuTyrValGlySerAsp     245250255     LeuGluIleGlyGlnHisArgThrLysIleGluGluLeuArgGlnHis     260265270     LeuLeuArgTrpGlyLeuThrThrProAspLysLysHisGlnLysGlu     275280285     ProProPheLeuTrpMetGlyTyrGluLeuHisProAspLysTrpThr     290295300     ValGlnProIleValLeuProGluLysAspSerTrpThrValAsnAsp     305310315320     IleGlnLysLeuValGlyLysLeuAsnTrpAlaSerGlnIleTyrPro     325330335     GlyIleLysValArgGlnLeuCysLysLeuLeuArgGlyThrLysAla     340345350     LeuThrGluValIleProLeuThrGluGluAlaGluLeuGluLeuAla     355360365     GluAsnArgGluIleLeuLysGluProValHisGlyValTyrTyrAsp     370375380     ProSerLysAspLeuIleAlaGluIleGlnLysGlnGlyGlnGlyGln     385390395400     TrpThrTyrGlnIleTyrGlnGluProPheLysAsnLeuLysThrGly     405410415     LysTyrAlaArgMetArgGlyAlaHisThrAsnAspValLysGlnLeu     420425430     ThrGluAlaValGlnLysIleThrThrGluSerIleValIleTrpGly     435440445     LysThrProLysPheLysLeuProIleGlnLysGluThrTrpGluThr     450455460     TrpTrpThrGluTyrTrpGlnAlaThrTrpIleProGluTrpGluPhe     465470475480     ValAsnThrProProLeuValLysLeuTrpTyrGlnLeuGluLysGlu     485490495     ProIleValGlyAlaGluThrPheTyrValAspGlyAlaAlaAsnArg     500505510     GluThrLysLeuGlyLysAlaGlyTyrValThrAsnArgGlyArgGln     515520525     LysValValThrLeuThrAspThrThrAsnGlnLysThrGluLeuGln     530535540     AlaIleTyrLeuAlaLeuGlnAspSerGlyLeuGluValAsnIleVal     545550555560     ThrAspSerGlnTyrAlaLeuGlyIleIleGlnAlaGlnProAspGln     565570575     SerGluSerGluLeuValAsnGlnIleIleGluGlnLeuIleLysLys     580585590     GluLysValTyrLeuAlaTrpValProAlaHisLysGlyIleGlyGly     595600605     AsnGluGlnValAspLysLeuValSerAlaGlyIleArgLysValLeu     610615620     PheLeuAspGlyIleAspLysAlaGlnAspGluHisGluLysTyrHis     625630635640     SerAsnTrpArgAlaMetAlaSerAspPheAsnLeuProProValVal     645650655     AlaLysGluIleValAlaSerCysAspLysCysGlnLeuLysGlyGlu     660665670     AlaMetHisGlyGlnValAspCysSerProGlyIleTrpGlnLeuAsp     675680685     CysThrHisLeuGluGlyLysValIleLeuValAlaValHisValAla     690695700     SerGlyTyrIleGluAlaGluValIleProAlaGluThrGlyGlnGlu     705710715720     ThrAlaTyrPheLeuLeuLysLeuAlaGlyArgTrpProValLysThr     725730735     IleHisThrAspAsnGlySerAsnPheThrGlyAlaThrValArgAla     740745750     AlaCysTrpTrpAlaGlyIleLysGlnGluPheGlyIleProTyrAsn     755760765     ProGlnSerGlnGlyValValGluSerMetAsnLysGluLeuLysLys     770775780     IleIleGlyGlnValArgAspGlnAlaGluHisLeuLysThrAlaVal     785790795800     GlnMetAlaValPheIleHisAsnPheLysArgLysGlyGlyIleGly     805810815     GlyTyrSerAlaGlyGluArgIleValAspIleIleAlaThrAspIle     820825830     GlnThrLysGluLeuGlnLysGlnIleThrLysIleGlnAsnPheArg     835840845     ValTyrTyrArgAspSerArgAsnSerLeuTrpLysGlyProAlaLys     850855860     LeuLeuTrpLysGlyGluGlyAlaValValIleGlnAspAsnSerAsp     865870875880     IleLysValValProArgArgLysAlaLysIleIleArgAspTyrGly     885890895     LysGlnMetAlaGlyAspAspCysValAlaSerArgGlnAspGluAsp     900905910     Xaa     __________________________________________________________________________ 

I claim:
 1. A method of testing for exposure of an organism to HIV, which comprises providing an HIV antigen, contacting said antigen with a sample from said organism and detecting any antigen-antibody complexes created as a result of said contact as indicative of exposure of said organism to HIV, said antigen being a polypeptide having the amino acid sequence of SEQ ID NO:22.
 2. A diagnostic kit for detecting antibodies to HIV antigens wherein said kit contains, as a test reagent, a polypeptide having the amino acid sequence of SEQ ID NO:22. 